



**UNIVERSITI PUTRA MALAYSIA**

***OPTIMIZATION, ENCAPSULATION AND CHARACTERIZATION OF  
BROMELAIN-GENERATED ANGIOTENSIN I-CONVERTING ENZYME  
(ACE)-INHIBITORY HYDROLYSATES FROM STONE FISH  
(*Actinopyga lecanora* Jaeger)***

**SHEHU MUHAMMAD AUWAL**

**FSTM 2018 27**



**OPTIMIZATION, ENCAPSULATION AND CHARACTERIZATION OF  
BROMELAIN-GENERATED ANGIOTENSIN I-CONVERTING ENZYME  
(ACE)-INHIBITORY HYDROLYSATES FROM STONE FISH  
(*Actinopyga lecanora* Jaeger)**

By

**SHEHU MUHAMMAD AUWAL**

**Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia,  
in Fulfillment of the Requirements for the Degree of Doctor of Philosophy**

**June 2018**

## **COPYRIGHT**

All material contained within the thesis, including without limitation text, logos, icons, photographs, and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



## **DEDICATION**

To my beloved parents

Thank you for all your supports and sacrifices



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Doctor of Philosophy

**OPTIMIZATION, ENCAPSULATION AND CHARACTERIZATION OF  
BROMELAIN-GENERATED ANGIOTENSIN I-CONVERTING ENZYME  
(ACE)-INHIBITORY HYDROLYSATES FROM STONE FISH  
(*Actinopyga lecanora* Jaeger)**

By

**SHEHU MUHAMMAD AUWAL**

**June 2018**

**Chairman : Professor Nazamid Saari, PhD**  
**Faculty : Food Science and Technology**

Stone fish is an under-utilized sea cucumber with many nutritional and ethno-medicinal values. Proteases-aided hydrolysis of stone fish protein was found to generate hydrolysates with strong antioxidant and ACE-inhibitory effects. However, the direct use of stone fish-derived hydrolysates as potential antihypertensive molecules is limited by their low stability against digestive enzymes and unpleasant fishy odor. Therefore, the present study aimed to optimize hydrolysis of stone fish protein for the production of angiotensin I-converting enzyme (ACE)-inhibitory hydrolysates using bromelain and improve the stability and ACE-inhibitory activity of the resulting hydrolysates against gastrointestinal digestion by nanoencapsulation. Response surface methodology (RSM) based on a central composite design (CCD) was used to model and optimize the degree of hydrolysis (DH) and ACE-inhibitory activity. A pH of 7.0, temperature of 40°C, E/S ratio of 2% and reaction time of 240 min were determined using a response surface model as the optimum levels to obtain the hydrolysates with maximum ACE-inhibitory activity of 84.26% at 44.59% degree of hydrolysis. The hydrolysates were further profiled in which five novel ACE-inhibitory peptides including ALGPQFY, KVPPKA, LAPPTM, EVLIQ and EHPVL were identified with their respective IC<sub>50</sub> values of 0.012 mM, 0.980 mM, 1.31 mM, 1.44 mM and 1.68 mM. The ACE-inhibitory hydrolysates were then nanoencapsulated in chitosan nanoparticles and optimized based on 3-factor 3-level Box–Behnken experimental design. The optimized nanoparticles showed a good physicochemical stability following their twelve weeks of storage at 4°C. The result of *in vitro* efficacy indicated significantly higher ( $p < 0.05$ ) ACE-inhibitory activity of 51.96% for the nanoparticles compared to 36.84% for the free hydrolysates following their simulated gastrointestinal digestion. The *in vivo* antihypertensive effect of the optimized nanoparticles was also evaluated on spontaneously

hypertensive rats within 24 h following single oral administration at 200 mg/kg, 400 mg/kg and 800 mg/kg. The results demonstrated significant systolic blood pressure lowering effects of the nanoparticles at all the three doses compared to the group treated with the unencapsulated hydrolysates. The nanoparticles were then evaluated for acute and sub-acute toxicity on liver and kidney of Wistar Kyoto rats. The result indicated no death with a safe dose limit of the nanoparticles greater than 2000 mg/kg. Serum biochemical analysis and histomorphological examination following 28 days of repeated exposure of the rats to the 200 mg/kg, 400 mg/kg and 800 mg/kg doses of the nanoparticles, revealed no alteration in the function and architecture of both liver and kidney with no occurrence of cellular necrosis. This indicated the safe therapeutic application of the chitosan nanoparticles loaded with stone fish-derived ACE-inhibitory hydrolysates to be utilized as food bio-ingredient for long term management of hypertension.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

**OPTIMISASI, ENKAPSULASI DAN PENCIRIAN HIDROLISAT  
PERENCAT ENZIM PENUKAR ANGIOTENSIN -1 (ACE) DARIPADA  
IKAN BATU (*Actinopyga lecanora* Jaeger) YANG DIHASILKAN MELALUI  
TINDAKAN BROMELAIN**

Oleh

**SHEHU MUHAMMAD AUWAL**

**Jun 2018**

**Pengerusi : Profesor Nazamid Saari, PhD**  
**Fakulti : Sains dan Teknologi Makanan**

Ikan batu adalah sejenis timun laut yang kurang dimanfaatkan walaupun mempunyai pelbagai nilai pemakanan dan etno-ubat. Protease-berbantu hidrolisis protein ikan batu didapati menghasilkan hidrolisat dengan antioksidan dan kesan perencatan ACE yang kuat. Walau bagaimanapun, penggunaan langsung hidrolisat ikan batu sebagai molekul antihipertensi yang berpotensi adalah terhad disebabkan oleh kestabilan yang rendah terhadap enzim pencernaan dan bau hanyir yang tidak menyenangkan. Oleh itu, kajian ini bertujuan untuk mengoptimumkan hidrolisis protein ikan batu untuk penghasilan hidrolisat perencat enzim penukar angiotensin I (ACE) dengan menggunakan bromelain dan meningkatkan kestabilan dan aktiviti hidrolisat perencat ACE terhadap pencernaan gastrointestinal melalui nanoenkapsulasi. Kaedah tindak balas permukaan (RSM) berdasarkan reka bentuk komposit pusat (CCD) digunakan untuk memodel dan mengoptimumkan darjah hidrolisis (DH) dan aktiviti perencatan ACE. Nilai pH 7.0, suhu 40°C, nisbah E/S sebanyak 2% dan masa tindak balas 240 min ditentu menggunakan model tindakbalas permukaan adalah tahap optimum untuk mendapatkan hidrolisat dengan aktiviti perencatan ACE maksimum sebanyak 84.26% pada tahap darjah hidrolisis 44.59%. Hidrolisat kemudian dipofilkan dimana lima peptida perencatan ACE baru termasuk ALGPQFY, KVPPKA, LAPPTM, EVLIQ dan EHPVL telah dikenalpasti dengan nilai  $IC_{50}$  masing-masing 0.012 mM, 0.980 mM, 1.31 mM, 1.44 mM dan 1.68 mM. Hidrolisat perencat ACE kemudiannya di nanoenkapsulasi dalam nanopartikel kitosan dan dioptimum berdasarkan reka bentuk eksperimen Box-Behnken 3-faktor 3-peringkat. Nanopartikel yang dioptimumkan menunjukkan kestabilan fizikokimia yang baik berikutan penyimpanan selama dua belas minggu pada 4°C. Dapatan daripada kajian keberkesanan secara *in vitro* menunjukkan peningkatan lebih tinggi yang signifikan ( $p < 0.05$ ) aktiviti perencatan ACE

sebanyak 51.96% bagi hidrolisat nanopartikel berbanding dengan 36.84% bagi hidrolisat bebas berikutan pencernaan gastrointestinal. Kesan antihipertensif secara *in vivo* bagi nanopartikel yang dioptimumkan juga dinilai ke atas tikus hipertensi secara spontan dalam masa 24 jam berikutan administrasi oral tunggal hidrolisat pada dos 200 mg/kg, 400 mg/kg dan 800 mg/kg. Dapatan menunjukkan kesan penurunan tekanan darah sistolik yang signifikan bagi nanopartikel pada tahap ketiga-tiga dos berbanding dengan kumpulan tikus yang dirawat dengan hidrolisat yang tidak dinanoenkapsulasikan. Nanopartikel tersebut kemudiannya dinilai untuk ketoksikan akut dan sub-akut ke atas hati dan ginjal tikus Kyoto Wistar. Dapatan menunjukkan tiada kematian dengan had dos selamat nanopartikel lebih besar daripada 2000 mg/kg. Analisis biokimia serum dan pemeriksaan histomorfologi berikutan pendedahan berulang tikus selama 28 hari kepada nanopartikel pada dos 200 mg/kg, 400 mg/kg dan 800 mg/kg, menunjukkan tiada perubahan dalam fungsi dan susunan struktur hati dan buah pinggang dengan tiada kejadian nekrosis selular. Ini menunjukkan aplikasi terapeutik yang selamat bagi nanopartikel kitosan yang dimuatkan dengan hidrolisat perencat ACE dari ikan batu dan boleh seterusnya digunakan sebagai bioramuan makanan untuk pengurusan jangka panjang tekanan darah tinggi.



## ACKNOWLEDGEMENTS

All praise is to Allah the owner of the universe who has created mankind and bestowed on to him knowledge and wisdom. I thank him for the strength and endurance which led to the successful completion of my study. Vehemently, I have to acknowledge the kind and scientific support through interaction with different professionals across various fields related to my area of study and particularly those from the Faculty of Food Science and Technology.

Firstly, I am sincerely grateful to my supervisor Prof. Dr. Nazamid Saari for his guidance, professional and constructive supervision from the inception of the project to the final compilation of this thesis.

I will also like to acknowledge the guidance and professional support I received from Prof. Dr. Chin Ping Tan. My sincere gratitude also goes to Late Prof. Dr. Mahiran Basri for her professional guidance right from the beginning of my study may her soul rest in perfect peace. My sincere appreciation also goes to Dr Mohammad Zarei for his guidance throughout the period of the study.

I am also indebted to the technical support given to me by laboratory scientists particularly those in the Faculty of Food Science and Technology and Faculty of Medicine and Health Sciences Universiti Putra Malaysia.

Finally, my deepest and heartfelt appreciation goes to my parents for their prayers, support and encouragement throughout my academic achievements.

This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

**Nazamid Saari, PhD**

Professor  
Faculty of Food Science and Technology  
Universiti Putra Malaysia  
(Chairman)

**Chin Ping Tan, PhD**

Professor  
Faculty of Food Science and Technology  
Universiti Putra Malaysia  
(Member)

**Mahiran Basri, PhD**

Professor  
Faculty of Science  
Universiti Putra Malaysia  
(Member)

**Amin Ismail, PhD**

Professor  
Faculty of Nutrition and Health Science  
Universiti Putra Malaysia  
(Member)

---

**ROBIAH BINTI YUNUS, PhD**  
Professor and Dean  
School of Graduate Studies  
Universiti Putra Malaysia

Date

## Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: \_\_\_\_\_  
Name of Chairman  
of Supervisory  
Committee: Professor Dr. Nazamid Saari

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Professor Dr. Chin Ping Tan

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Professor Dr. Mahiran Basri

Signature: \_\_\_\_\_  
Name of Member  
of Supervisory  
Committee: Professor Dr. Amin Ismail

## TABLE OF CONTENTS

	<b>Page</b>
<b>ABSTRACT</b>	i
<b>ABSTRAK</b>	iii
<b>ACKNOWLEDGEMENTS</b>	v
<b>APPROVAL</b>	vi
<b>DECLARATION</b>	viii
<b>LIST OF TABLES</b>	xvi
<b>LIST OF FIGURES</b>	xvii
<b>LIST OF ABBREVIATIONS</b>	xxii
 <b>CHAPTER</b>	
<b>1 INTRODUCTION</b>	<b>1</b>
1.1 Background	1
1.2 Problem Statement	5
1.3 Objectives	5
 <b>2 LITERATURE REVIEW</b>	 <b>6</b>
2.1 Sea Cucumber	6
2.1.1 Classification	6
2.1.2 Stone fish ( <i>Actinopyga lecanora</i> )	6
2.1.3 Sea Cucumber as a Source of Food	7
2.1.4 Human Health Benefits of Sea Cucumber	8
2.1.5 Sea Cucumber as a Source of Protein	8
2.2 Angiotensin I-Converting Enzyme and Its Role in the Mechanism of Hypertension	9
2.3 Hypertension as a Cardiovascular Risk Factor	11
2.4 Marine Derived ACE-Inhibitory Hydrolysates and Peptides in the Management of Hypertension	11
2.5 Generation of Antihypertensive Protein Hydrolysates and Peptides from Marine Organisms	11
2.6 Optimization of the Generation of Food Protein Hydrolysates Using Response Surface Methodology	12
2.6.1 Screening of Independent Variables	12
2.6.2 Selection of a Regression Model	13
2.6.3 Coding the Factor Levels	13
2.6.4 Design of Experiments (DoE)	14
2.6.4.1 Full Factorial Design (FFD)	14
2.6.4.2 Box-Behnken Design (BBD)	14
2.6.4.3 Central Composite Design (CDD)	15
2.6.4.4 Enzymatic Hydrolysis of Food Proteins using RSM	17

2.7	Antihypertensive Mode of Marine Derived ACE-inhibitory Hydrolysates and Peptides	20
2.8	Structure–Activity Relation of Marine-Derived Antihypertensive Peptides	27
2.9	<i>In vivo</i> Antihypertensive Effect of ACE-Inhibitory Protein Hydrolysates and Peptides in Rats	28
2.10	<i>In vivo</i> Human Studies of Marine Derived Antihypertensive Protein Hydrolysates and Peptides	31
2.11	Marine Derived Antihypertensive Protein Hydrolysates and Peptides as Bioactive Food Ingredients	32
2.12	Bioavailability of Marine-Derived Antihypertensive Peptides	35
	2.12.1.1 Intestinal Transport System for Bioactive Peptides	36
2.13	Strategies to Improve Bioavailability of ACE-inhibitory Protein Hydrolysates and Peptides	37
	2.13.1 Structural and Chemical Modification	38
	2.13.2 Micro- and Nanoparticle- Based Delivery Systems	38
	2.13.2.1 Protein-Based Nano and Micron Carriers for Protein Hydrolysates and Peptides	39
	2.13.2.2 Polysaccharide-Based Carriers for Protein Hydrolysates and Peptides	39
	2.13.2.3 Lipid-Based Carriers for Protein Hydrolysates and Peptides	40
2.14	Methods for the Encapsulation of Protein Hydrolysates and Peptides	41
	2.14.1 Lipid Film Hydration Method	41
	2.14.2 Spray Drying Method	41
	2.14.3 Coacervation Method	42
	2.14.4 Ionotropic Gelation Method	42
2.15	Optimization of Micro- and Nanoparticles Based Encapsulation of Protein Hydrolysates and Peptides	42
2.16	Parameters for Assessing the Quality of Encapsulated Protein Hydrolysates and Peptides	44
	2.16.1 Particle Size	44
	2.16.2 Zeta Potential	44
	2.16.3 Encapsulation Efficiency (EE)	45
2.17	Nanoparticles Toxicity	46
<b>3</b>	<b>RESPONSE SURFACE OPTIMIZATION AND PROFILING OF BROMELAIN-GENERATED ANGIOTENSIN CONVERTING ENZYME (ACE)-INHIBITORY HYDROLYSATES FROM STONE FISH (<i>Actinopyga lecanora</i>)</b>	<b>50</b>
3.1	Introduction	50
3.2	Materials and Methods	51
	3.2.1 Raw Materials	51
	3.2.2 Chemicals	51
	3.2.3 Methods	51

3.2.3.1	Proximate Composition Analysis of Whole Milled Stone Fish ( <i>A. lecanora</i> )	51
3.2.3.2	Preparation of Stone Fish Hydrolysates (SHs) Under Optimum Hydrolysis Conditions (pH, Temperature, Enzyme/Substrate Ratio and Time) Using Bromelain	53
3.2.3.3	Profiling of Stone Fish Protein Hydrolysates Produced Under Optimum Hydrolysis Conditions	55
3.2.3.4	Peptide Sequencing Protocol Using Q-TOF LC/MS	56
3.2.3.5	Database Searching	57
3.2.3.6	Determination of Degree of Hydrolysis (DH) Using O-phthaldialdehyde (OPA)	57
3.2.3.7	Determination of ACE-Inhibitory Activity	58
3.3	Results and Discussion	58
3.3.1	Proximate Composition	58
3.3.2	Generation of Stone Hydrolysates under Optimum Hydrolysis Conditions of pH, Temperature, Enzyme/Substrate Ratio and Time Using Bromelain	60
3.3.2.1	Effect of Hydrolysis pH, Temperature, Enzyme/Substrate Ratio and Time on Degree of Hydrolysis	60
3.3.2.2	Effect of Hydrolysis pH, Temperature, E/S Ratio and Time on ACE-Inhibitory Activity	62
3.3.2.3	Model Validation of the Optimum predicted Conditions of pH, Temperature, Enzyme/Substrate Ratio and Time for the Maximum Degree of Hydrolysis and ACE-inhibitory Activity of Stone Fish Hydrolysates	63
3.3.3	Profiling of Stone Fish Protein Hydrolysates Produced Under Optimum Hydrolysis Conditions	67
3.3.3.1	Profiling Based on Hydrophobicity Using a Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) and ACE-Inhibitory Activity of the Fractions	67
3.3.3.2	Fractionation Based on Isoelectric Properties Using Isoelectric Focusing (IEF) Electrophoresis and ACE-Inhibitory Activity of the Fractions	70
3.4	Analysis of Peptide Sequence and ACE-inhibitory Activity	71
3.5	Conclusion	78

<b>4</b>	<b>NANOENCAPSULATION FOR THE IMPROVEMENT OF PHYSICOCHEMICAL AND <i>IN VITRO</i> GASTROINTESTINAL STABILITY OF STONE FISH- DERIVED ACE-INHIBITORY HYDROLYSATES</b>	<b>79</b>
4.1	Introduction	79
4.2	Materials and Methods	80
4.2.1	Raw Materials	80
4.2.2	Chemicals	80
4.3	Methods	80
4.3.1	Preparation of Stone Fish Hydrolysates (SHs) Under Optimum Hydrolysis Conditions (pH, Temperature, Enzyme/Substrate Ratio and Time) Using Bromelain	80
4.3.2	Preparation of Nanoliposome Containing Stone fish-Derived ACE-Inhibitory Hydrolysates (NL-SHs-LFH) by Lipid Film Hydration Method	80
4.3.3	Preparation of Nanoliposome Containing ACE-inhibitory Hydrolysates (NL-SHs-DHM) by Direct Hydration Method	81
4.3.4	Preparation of Chitosan-TPP Nanoparticles Containing Stone fish-Derived ACE-inhibitory Hydrolysates (SHs loaded Chit:TPP NPs) by Iontropic Gelation Method	81
4.3.5	Selection of the Encapsulation Technique and Optimization of the Resulting Nanoparticles with Higher Physicochemical Stability and Extended <i>In vitro</i> Release	82
4.3.5.1	Experimental design and Model Building to Fabricate SHs loaded Chitosan:TPP NPs for the Optimum Responses (Particle size and Encapsulation Efficiency)	82
4.4	Analytical Procedures	83
4.4.1	Determination of Encapsulation Efficiency	83
4.4.1.1	Encapsulation Efficiency of NL-SHS-LFH and NL-SHs-DHM	83
4.4.1.2	Encapsulation Efficiency of SHs loaded Chit:TPP NPs	84
4.4.1.3	Determination of Particle Size, Polydispersity Index and Zeta potential	85
4.4.1.4	Determination of the Encapsulated and Unencapsulated SHs Concentration	85
4.4.2	Determination of <i>In vitro</i> Release	85
4.4.3	Determination of ACE-Inhibitory Activity	86
4.4.4	Evaluation of <i>In vitro</i> Gastrointestinal Digestion and Residual ACE-Inhibitory Activity of the NL-SHS-LFH, NL-SHs-DHM and SHs loaded Chit:TPP NPs Under Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF)	86

4.4.4.1	<i>In vitro</i> Gastrointestinal Digestion and Residual ACE-Inhibitory Activity of the NL-SHS-LFH and NL-SHs-DHM Under Stimulated-Gastric Fluid (SGF) and Stimulated-Intestinal Fluid (SIF)	86
4.4.4.2	<i>In vitro</i> Gastrointestinal Digestion and Residual ACE-Inhibitory Activity of the SHs loaded Chit: TPP NPs Under Stimulated-Gastric Fluid (SGF) and Stimulated-Intestinal Fluid (SIF)	87
4.4.5	Physicochemical Characterization of the SHs loaded Chit: TPP NPs Fabricated Under Optimum Levels of Process Variables	87
4.4.5.1	Fourier Infrared Spectroscopy	87
4.4.5.2	X-ray Diffraction Analysis	88
4.4.5.3	Thermogravimetric Analysis	88
4.4.5.4	Transmission Electron Microscopy (TEM)	88
4.5	Results and Discussion	88
4.5.1	Physicochemical Stability-Aided Screening of the Encapsulation Technique for the Selection and Optimization of the SHs Entrapped Nanocapsules	88
4.5.1.1	Physicochemical Stability of the NL-SHS-LFH, NL-SHs-DHM Prepared by Lipid Film Hydration and Direct Hydration Methods	88
4.5.1.2	Physicochemical Stability of the SHS loaded Chit:TPP NPs Prepared by Iontropic Gelation Method	92
4.5.1.3	Selection of SHs Entrapped Nanocapsules with High Physicochemical Stability	96
4.5.2	Graphical Optimization and Model Fitting	97
4.5.3	Physicochemical Stability of the Optimized Chitosan-TPP Nanocapsules Containing the ACE- inhibitory Hydrolysates	105
4.5.3.1	Particle Size, Pdi, Zeta potential and Encapsulation Efficiency	105
4.5.4	Physicochemical Characterization of the Optimized Chitosan-TPP Nanocapsules Containing the ACE-inhibitory Hydrolysates	107
4.5.4.1	FTIR Spectroscopy	107
4.5.4.2	XRD Analysis	108
4.5.4.3	<i>In vitro</i> SHs release	110
4.5.4.4	<i>In vitro</i> Gastrointestinal Digestion and ACE-inhibitory Activity	111
4.5.4.5	Differential Scanning Calorimetry (DSC)	112
4.5.4.6	Transmission Electron Microscopy (TEM)	114
4.6	Conclusion	114



<b>5</b>	<b>EVALUATION OF <i>IN VIVO</i> ANTIHYPERTENSIVE AND TOXICITY EFFECTS OF SHS LOADED CHIT:TPP NPS IN RATS</b>	116
5.1	Introduction	116
5.2	Materials and Methods	118
5.2.1	Raw Materials	118
5.2.2	Animals	118
5.2.3	Chemicals	118
5.3	Methods	119
5.3.1	Preparation of Stone Fish-Derived ACE-Inhibitory Hydrolysates (SHs) Under Optimum Hydrolysis Conditions (pH, Temperature, Enzyme/ Substrate Ratio and Time) Using Bromelain	119
5.3.2	Preparation of SHs loaded Chit:TPP NPs under Optimum Condition by Iontropic Gelation Method	119
5.3.3	Evaluation of <i>In vivo</i> Antihypertensive Effect of the SHs loaded Chit:TPP NPs on Blood Pressure of Spontaneously Hypertensive Rats	119
5.3.4	Evaluation of <i>In vivo</i> Toxicity of the SHs loaded Chitosan:TPP NPs on Liver and Kidney of Wistar Kyoto Rats	119
5.3.4.1	Biochemical Analysis	120
5.3.4.2	Histomorphological examination	120
5.4	Results and Discussion	121
5.4.1	<i>In vivo</i> Antihypertensive Effect of the SHs loaded Chit:TPP NPs in SHRs	121
5.4.2	Toxicological Evaluation of the SHs loaded Chito:TPP NPs	123
5.4.2.1	Effect of SHs loaded Chit:TPP NPs on Body Weight of Wistar Kyoto Rats	123
5.4.2.2	Acute and Sub-Acute Toxicity of SHs loaded Chit:TPP NPs in Wistar Kyoto Rats	125
5.5	Conclusions	129
<b>6</b>	<b>SUMMARY, CONCLUSIONS AND RECOMMENDATION FOR FUTURE RESEARCH</b>	130
6.1	Summary	130
6.2	General Conclusion	132
6.3	Recommendation for Future Research	133
	<b>REFERENCES</b>	134
	<b>APPENDICES</b>	169
	<b>BIODATA OF STUDENT</b>	172
	<b>LIST OF PUBLICATIONS</b>	173

## LIST OF TABLES

Table		Page
2.1	Experimental matrices for three level variables using RSM designs	17
2.2	Antioxidant and ACE-inhibitory activity of protease-generated protein hydrolysates optimized using RSM	19
2.3	Marine protein hydrolysates-derived angiotensin I-converting enzyme (ACE)-inhibitory peptides	22
2.4	Commercially available product enriched with marine derived antihypertensive protein hydrolysates and peptides	34
2.5	Short- and long- term acute and sub-acute toxicity studies of nanoparticles in different rats model	47
3.1	Coded and uncoded levels of the process variables for the CCD design optimization of degree of hydrolysis and ACE-inhibitory activity of stone fish using bromelain	54
3.2	Central composite experimental design for the optimization of degree of hydrolysis and ACE-inhibitory activity of stone fish using bromelain under different levels of process variables	55
3.3	Proximate composition of freeze-dried stone fish ( <i>Actinopyga lecanora</i> ) sample powder in comparison with other Sea Cucumber Species	59
3.4	Experimental validation of the predicted values of ACE-inhibitory activity and DH under the optimum hydrolysis conditions of pH 7, temp 40°C, E/S 2% and time 240 min	65
3.5	Central composite experimental design, predicted and response values of the two dependent variables under different reaction conditions	66
3.6	Analysis of variance and estimated regression coefficients for DH (Y1) and ACE-inhibitory activity (Y2) quadratic models	67
3.7	ACE-inhibitory effect of the RP-HPLC and IEF fractions	70
3.8	Characteristics of the Potent ACE-inhibitory peptide sequences identified from the RP-HPLC and IEF fractions	76
4.1	Uncoded levels of the process variables for the fabrication of SHs loaded Chit:TPP NPs using Box-Behnken design	83

4.2	Box-Behnken experimental design for the optimization of particle size and encapsulation efficiency of SHs loaded Chit:TPP NPs fabricated by ionotropic gelation	83
4.3	Comparison of the physicochemical properties of nanocapsules containing stone fish-derived ACE-inhibitory hydrolysates prepared by three encapsulation techniques following 8 weeks of storage at 4°C	96
4.4	Experimental and predicted values of response variables for Box-Behnken design	97
4.5	Experimental validation of the predicted values of particle size (nm) and EE under the optimum encapsulation conditions of A (0.35), B (8000 rpm) and C (30min)	100
4.6	Analysis of variance for mean particle size ( $R_1$ ) and Encapsulation efficiency ( $R_2$ ) of the fitted quadratic model	104
4.7	Changes in the enthalpies obtained from DSC thermograms of empty Chit:TPP NPs and SHs loaded Chit:TPP NPs	113
5.1	The magnitude of systolic blood pressure reduction due to a single oral dose on spontaneously hypertensive rats (SHRs) as mean $\pm$ standard deviation (mmHg) within 24 h post administration	122

## LIST OF FIGURES

Figure	Page
2.1 Stone fish ( <i>Actinopyga lecanora</i> )	7
2.2 Role of Angiotensin I-Converting Enzyme in Blood Pressure Regulation	10
2.3 Experimental designs for a study with all variables at three levels. (a) Full factorial design (FFD); (b) Box-Behnken design (BBD); (c) Central composite design (CCD)	16
2.4 Intestinal transport mechanisms of peptides; paracellular mechanism: (a) passive movement between cells and through tight junctions, transcellular mechanism: (b) passive diffusion across cell membrane; (c) carrier-mediated active transport and (d) vesicular transport	37
3.1 Response surface plots for the effects of independent factors/process variables on degree of hydrolysis: (a) pH and E/S ratio; (b) temperature and time (c) enzyme/substrate (E/S) ratio and time	61
3.2 Response surface plots for the effects of the independent factors on angiotensin I-converting enzyme (ACE)-inhibitory activity: (a) pH and temperature; (b) pH and E/S ratio; (c) temperature and E/S ratio (d) temperature and time	63
3.3 Response optimization for the hydrolysis parameters, predicted responses, and their level of desirability. Y1 = degree of hydrolysis (DH, %), Y2 = ACE-inhibitory activity (%), D = Composite desirability for Y1 and Y2 responses, d1 = individual desirability of Y1, d2 = individual desirability of Y2. Optimum selected conditions of pH, temperature, enzyme/substrate ratio and time are shown in red whereas the maximum predicted responses of Y1 and Y2 are shown in blue	64
3.4 Hydrophobicity-based fractionation of bromelain-generated stone fish protein hydrolysate: (a) Chromatogram of bromelain-generated stone fish hydrolysate separated by semi-preparative RP-HPLC; (b) ACE-inhibitory activities of each of the potent fraction; (c) Relation between ACE-inhibitory activity and percentage acetonitrile being used	69
3.5 ACE-inhibitory activity of bromelain-generated stone fish hydrolysate fractions at different isoelectric points. Error bars indicate standard deviation.	71

3.6	MS/MS spectra, ion tables, MS/MS fragments and standard error of the potent peptide sequences with mw <1 kDa: (a) ALGPQFY; (b) KVPPKA;(c) LAPPTM; (d) EVLIQ; (e) EHPVL	74
3.7	ACE- inhibitory activity and IC <sub>50</sub> values of the potent peptide sequences derived from stone fish with mw <1 kDa: (a) ALGPQFY; (b) KVPPKA; (c) LAPPTM; (d) EVLIQ; (e) EHPVL hydrolysates using bromelain	75
4.1	Encapsulation efficiencies of the nanoliposome containing stone fish derived ACE-inhibitory hydrolysates prepared by lipid film hydration method (NL-SHs-LFH) and direct hydration method (NL-SHs-DHM). Error bars indicate standard deviation	89
4.2	Changes in the physical stability indices of the nanoliposome containing stone fish derived ACE-inhibitory hydrolysates prepared by lipid film hydration method (NL-SHs-LFH) and direct hydration method (NL-SHs-DHM): (a) Changes in particle size and pdi of NL-SHs-LFH; (b) Changes in particle size and pdi of NL-SHs-DHM; (c) Changes in zeta potential with changes in particle size (nm) of NL-SHs-LFH; (d) Changes in zeta potential with changes in particle size (nm) of NL-SHs-DHM. Error bars indicate standard deviation	91
4.3	Cumulative release profile of the nanoliposome containing SHs prepared by lipid film hydration method (NL-SHs-LFH) and direct hydration method (NL-SHs-DHM)	92
4.4	Changes in the encapsulation efficiency of chitosan nanoparticles containing ACE-inhibitory SHs prepared by ionotropic gelation at a Chitosan:TPP mass ration of 4:1 (SHs loaded Chit:TPP NPs). Error bars indicate standard deviation	93
4.5	Changes in particle size and polydispersity index (pdi) of chitosan nanoparticles containing ACE-inhibitory SHs prepared by ionotropic gelation at a Chitosan:TPP mass ration of 4:1 (SHs loaded Chit:TPP NPs). Error bars indicate standard deviation.	94
4.6	Changes in zeta potential (mV) of chitosan nanoparticles containing ACE-inhibitory SHs prepared by ionotropic gelation method at a Chitosan:TPP mass ration of 4:1 (SHs loaded Chit:TPP NPs). Error bars indicate standard deviation.	95
4.7	: Cumulative release profile of the SHs loaded Chit:TPP NPs prepared by ionotropic gelation method	96
4.8	Response optimization for the formulation of SHs loaded Chit:TPP NPs, composite and individual desirabilities (D, d <sub>1</sub> and d <sub>2</sub> ) of the predicted outcomes R <sub>1</sub> = particle size (nm), R <sub>2</sub> = Encapsulation	

	efficiency (%), A (SHs:Chitosan mass ratio), B (Homogenization speed and (C) Homogenization time	98
4.9	Effect of formulation parameters on the particle size (nm) and encapsulation efficiency (EE, %) of SHs loaded Chit:TPP NPs (a) SHs:Chitosan mass ratio; (b) Homogenization speed; (c) and Homogenization time	99
4.10	Three dimensional response surface plots for the effect of process conditions on; (1). Particle size (nm): (a) SHs:Chitosan mass ratio (A) and Homogenization speed (B); (b) SHs:Chitosan mass ratio (A) and Homogenization time (C); (c) Homogenization speed (B) and Homogenization time (C), (2). Encapsulation efficiency (%): (d) SHs:Chitosan mass ratio (A) and Homogenization speed (B); (e) SHs:Chitosan mass ratio (A) and Homogenization time (C); (f) Homogenization speed (B) and Homogenization time (C)	102
4.11	Physical properties of SHs loaded Chit:TPP NPs; (a) particle size and pdi, (b) zeta potential	105
4.12	Changes in the physicochemical properties of the optimized SHs loaded Chit:TPP NPs during three months of storage at 4°C (a) Particle size and polydispersity index (pdi) (b) zeta potential ( $\zeta$ ) and (c) Encapsulation efficiency. Error bars indicate standard deviation	106
4.13	FTIR spectra of the empty Chit:TPP NPs and SHs loaded Chit:TPP NPs prepared under optimum condition	108
4.14	XRD spectra of the empty Chitosan:TPP Nanoparticles and SHs loaded Chit:TPP NPs prepared under optimum condition	109
4.15	<i>In vitro</i> cumulative release profile of the encapsulated SHs from the SHs loaded Chit:TPP NPs following 12 h of incubation in phosphate buffered saline, pH 7.4	110
4.16	ACE-inhibitory activity of free SHs and SHs loaded Chit:TPP NPs before and after simulated GIT digestion, different letters indicated significant difference ( $p < 0.05$ )	111
4.17	Differential scanning calorimetry (DSC) of the SHs loaded Chit:TPP NPs; (a) DSC curve of the empty chitosan nanoparticles and (b) DSC curve of the SHs loaded Chit:TPP NPs	112
4.18	TEM images of the SHs loaded Chit:TPP NPs	114
5.1	Systolic blood-pressure-lowering effect of unencapsulated SHs, captopril and three doses of SHs loaded Chit:TPP NPs within 24 h of single oral administration on SHR. Error bars indicate standard deviation	123

- 5.2 Changes in body weight of (a) Male (b) Female rats during 28 days of single oral dose with normal saline (group I); 800 mg/kg empty Chit:TPP NPs (group II); 200 mg/kg, 400 mg/kg and 800 mg/kg SHs loaded Chitosan:TPP NPs (groups III, IV and V). Error bars indicate standard deviation 124
- 5.3 Effect of SHs loaded Chitosan:TPP NPs on (a) Liver function and (b) Kidney function parameters following 28 days of single oral dose with normal saline (group I); 800 mg/kg empty Chit:TPP NPs (group II); 200 mg/kg, 400 mg/kg and 800 mg/kg SHs loaded Chit:TPP NPs (groups III, IV and V). Error bars indicate standard deviation. 126
- 5.4 Effect of SHs loaded Chit:TPP NPs on histomorphological features of liver and kidney tissues (H & E  $\times 200$ ). Liver (A, B, C, D & E); Kidney (F, G, H, I & J); (A & F): Normal saline; (B & G): empty Chit:TPP NPs, 800 mg/kg; (C & H): SHs loaded Chit:TPP NPs, 200 mg/kg; (D & I): SHs loaded Chit:TPP NPs, 400 mg/kg; (E & J): SHs loaded Chit:TPP NPs, 800 mg/kg; CV: central vein; PV: portal vein; HA: hepatic artery; BD: bile duct; SN: sinusoids; GM: glomerulus; PT: proximal tubules; DT: distal tubules; BS: bowman's space 128

## LIST OF ABBREVIATIONS

ACE	Angiotensin I-Converting enzyme
AOAC	Association of analytical communities
ACN	Acetonitrile
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
ANOVA	Analysis of variance
ARBs	Angiotensin II Receptor Blockers
AST	Aspartate aminotransferase
AT <sub>1</sub>	Angiotensin II receptor type 1
BCA	Bicinchoninic Acid
BD	Bile duct
BP	Blood pressure
BS	Bowman's space
BW	Body weight
CDD	Central composite design
CID	Collision induced dissociation
CV	Central vein
CVDs	Cardiovascular diseases
DBP	Diastolic blood pressure
DH	Degree of hydrolysis
DHM	Direct hydration method
DT	Distal tubules
DTT	Dithiothreitol
E/S	Enzyme-substrate ratio
FOSHU	Foods for Specified Health Uses
GI	Gastrointestinal



GIT	Gastrointestinal tract
GM	Glomerulus
HA	Hepatic artery
HCL	Hydrochloric acid
H&E	Haematoxylin and eosin
HHL	Hippuryl histidyl leucine
HPLC	High performance liquid chromatography
H <sub>2</sub> SO <sub>4</sub>	Sulphuric acid
IC <sub>50</sub>	Concentration of an inhibitor where the response is reduced by half
IEF	Isoelectric focusing
IPG	Immobilized pH gradient gel strip
L-NAME	L-nitro-arginine methyl ester
LC/MS	Liquid chromatography tandem mass spectrometry
LD <sub>50</sub>	Amount of an ingested substance that kills 50 percent of a test sample
LFH	Lipid film hydration
MS/MS	Tandem mass spectrometry
MWCO	Molecular weight cut off
NO	Nitric oxide
NOS	Nitric oxide synthase
NPs	Nanoparticles
OPA	O-phthaldialdehyde
PC	Phosphatidyl choline
PT	Proximal tubules
PV	Portal vein
Q-SAR	Quantitative structure–activity relationship
Q-TOF	Quadrupole time-of-flight
RASS	Renin Angiotensin Aldosterone System
RP-HPLC	Reversed-Phase High-Performance Liquid Chromatography

RSM	Response surface methodology
SBP	Systolic blood pressure
SHRs	Spontaneously hypertensive rats
SHs	Stone fish derived ACE-inhibitory hydrolysates
SN	Sinusoids
TFA	Trifluoroacetic acid
TPP	Tripolyphosphate
WHO	World health organization
UV	Ultraviolet



# CHAPTER 1

## INTRODUCTION

### 1.1 Background

Angiotensin I-converting enzyme (ACE) acts as a key enzyme in blood pressure regulation via its dual effects on the renin-angiotensin as well as the kinin-kallikrein pathways. The Zn-containing peptidyl dipeptide hydrolase triggers the conversion of Angiotensin I to a potent vasopressor, Angiotensin II (Ariyoshi, 1993), and promotes the inactivation of bradykinin, an active vasodilator, resulting in elevated blood pressure or hypertension (Barbana & Boyce, 2011). The mechanism of the vasopressor effect involves the release of aldosterone, a sodium-retaining steroid from the adrenal cortex (Wijesekara & Kim, 2010).

Hypertension is defined as a sustained increase in systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure less than 90 mmHg. It is inferred as a common public health risk of global concern that is associated with cardiovascular related diseases such as heart failure, kidney failure, stroke and disability (Sun et al., 2014; WHO, 2013). Cardiovascular diseases have been identified as the major cause of mortality with a global death rate of greater than 17.30 million cases in 2013 which accounted for 31% of all the reported deaths during the year (Naghavi et al., 2015; Roth et al., 2015). The rate of death incidence due to poorly controlled CVDs is expected to exceed 23.60 million worldwide by 2030 (Go et al., 2013). However, it has been previously projected that a 34% decrease in premature death due to CVDs in the vulnerable group (30 to 70 yrs) could be achieved by the year 2025 through specifically targeting smoking, alcoholism, obesity, elevated blood pressure, glucose and salt intake as the major risks factors (Kontis et al., 2014).

More importantly, suppression of hypertension/elevated blood pressure alone among other risk factors could sufficiently reduce mortality due to CVDs by 30.40% and 38.00% in males and females respectively (Patel et al., 2015). In this regard, inhibition of ACE by decreasing angiotensin II formation and increasing bradykinin production is among the necessary strategies to control elevated blood pressure or hypertension (Girgih et al., 2016; Van der Ven et al., 2002). Presently, ACE-inhibitors, renin inhibitors, aldosterone inhibitors, beta blockers and angiotensin receptor blockers are the five major classes of antihypertensive drugs with specific target site inhibitory action on renin-angiotensin-aldosterone system (RAAS) that are used in the management of hypertension. However, the therapeutic potential of such drugs is limited by their cost and related adverse effects including insulin resistance and diabetes, skin rashes and taste disturbance etc (Geng et al., 2016; Soltani et al., 2015).

Alternatively, ACE-inhibitory hydrolysates are generated as mixture of peptides known as biopeptides through enzymatic hydrolysis of food proteins and have been reported to exhibit blood pressure lowering effects in hypertensive animals with little or no side effects (Adams et al., 2016; Beltrán-Barrientos et al., 2016; Norris et al., 2013; Sharma et al., 2011). In contrast to synthetic drugs, the food derived antihypertensive hydrolysates / biopeptides can be cheaply produced from certain proteins obtained from locally available food sources. Furthermore, the protein hydrolysates and their isolated constituent peptides with ACE-inhibitory activities are the most studied among the different classes of food biopeptides (Iwaniak et al., 2014). Food derived antihypertensive peptides have been associated with safe effects and exhibit their role through the inhibition of ACE (Chakrabarti et al., 2014; Udenigwe & Aluko, 2012). Thus, the food biopeptides can be used as alternative to synthetic drugs such as enalapril and lisinopril which are often accompanied with certain adverse effects such as thirst, diarrhea, skin rashes, fever and headache (Meresa et al., 2017; Kim et al., 2013). Food biopeptides occur as inactive sequences within the primary structure of their parent protein and are released via properly-designed enzymatic hydrolysis.

Among other potential sources, marine invertebrates are naturally endowed with valuable proteins that can be exploited in the production of functional hydrolysates and their constituent's peptides. Many peptides exhibiting one or more biological activities including those for the production of antimicrobial, antioxidant, antithrombotic, anti-Alzheimer, opiate and antihypertensive activity originating from marine invertebrates have been reported (Lee et al., 2012). Antihypertensive/ACE-inhibitory biopeptides have been generated from both animals and plant proteins including those of marine invertebrates (Wang et al., 2017; Li et al., 2016; Kim et al., 2013; Lee et al., 2012).

Similarly, the stone fish (*Actinopyga lecanora*) used in this study is a marine invertebrate that belongs to the phylum echinoderm and class Holothuroidea. It is categorized among the edible species of sea cucumber that are common to Malaysia and other south-Asian sea shores where it is collected by hand picking, free-diving and as by-catch of the fishing industry (Ghanbari et al., 2012; Conand et al., 2010). Despite being abundantly available, easy to propagate and with great commercial potential, the species is still under-utilized. Several biological effects, including antioxidant- (Bordbar et al., 2013), antibacterial- and antihypertensive (Ghanbari et al., 2015; Ghanbari et al., 2012) effects have been ascribed to stone fish hydrolysates produced using different proteases. *In vitro* and *in vivo* experiments with bromelain-generated hydrolysates of stone fish indicated their significant inhibitory capacity against the angiotensin I-converting enzyme activity (Vishkaei et al., 2016; Ghanbari et al., 2015). However, most of the ACE-inhibitory hydrolysates derived from marine invertebrates were reported to exhibit low bioactivity that varies with the type of hydrolyzing enzyme being used (Ghanbari et al., 2015). Thus, the choice of an appropriate enzyme is critical for obtaining inhibitory hydrolysates/biopeptides with strong activity against ACE. As previously reported, alcalase and bromelain-generated hydrolysates yielded the highest ACE-inhibitory activity when stone fish

was hydrolyzed by six different proteases whereas the activity decreased with trypsin, papain, pepsin, and flavourzyme generated hydrolysates (Ghanbari et al., 2015).

A series of chromatographic techniques including reverse phase high performance liquid chromatography, isoelectric focusing electrophoresis and LC/MS mass spectrometry are used in the profiling of protein hydrolysates/biopeptides (complex mixture of peptides) to ease the identification of the potent ACE-inhibitory peptide sequences (Zarei et al., 2015; Yea et al., 2014). In this regard, enzyme-generated protein hydrolysates with the highest ACE-inhibitory activity are selected and profiled to identify the peptide sequences present. The purified peptides can be synthesized as food grade or non-food grade. The production of both forms is costly and not economical. In addition, the non-food grade peptides cannot be directly used as functional ingredient or incorporated into foods. Thus, the natural forms of the peptides or their mixture (protein hydrolysates/biopeptides) which preserve the nutritional quality and constitute the net activity of the whole peptides present are safely and cheaply used for food and commercial purposes. Therefore, the profiling protocol including the identification, synthesis and characterization of the purified peptides are to provide evidence about the suitability of their protein hydrolysates/biopeptides mixture as antihypertensive bioactive ingredients for application in functional foods.

Functional food products enriched with bioactive ingredients such as the ACE-inhibitory hydrolysates are intended for oral consumption to aide in the management of hypertension. The oral route is more preferred for being safe, non-toxic and inexpensive. However, orally administered protein hydrolysates/biopeptides are susceptible to degradation by gastrointestinal enzymes and need to be protected for effective oral-colon delivery and biological efficacy. This can be achieved through encapsulation to safe guard their structural and functional integrity and to improve their stability against gastrointestinal proteases and peptidases (Mohan et al., 2015). Hence, encapsulation has become a relevant and important technology to promote the utilization of bioactive protein hydrolysates as functional food bioingredients for human health promotion. It protects the biopeptides against physicochemical modifications and enhances their bioavailability both *in vitro* and *in vivo* (Patel et al., 2014).

Several approaches including permeation enhancers, enzyme inhibitors, lipid based delivery and different polymeric carrier systems have been used to overcome these challenges (Sajeesh et al., 2015; Renukuntla et al., 2013). In this regard, nanoencapsulation become the most desirable approach to protect the protein hydrolysates and peptides against digestive enzymes, enhance their cellular uptake and controlled release for effective oral-colon delivery and biological efficacy (Niu et al., 2016; Renukuntla et al., 2013). By the virtue of their large surface area to volume ratio, the small size nanocapsules have been reported to circumvent first pass effect and improve the solubility, gastrointestinal stability, target site delivery, bioavailability and biological role of the encapsulated bioactive agent (Shegokar et

al., 2010). In due course, the nanoparticles prolong the half-life or retention time and reduce the dosing frequency of the incorporated antihypertensive peptides (Alam et al., 2017). The selection of appropriate biocompatible and biodegradable wall material is necessary to meet safety requirements for health concern about their possible toxicity especially when nanocarriers are used for the delivery of the bioactive agents (Aggarwal et al., 2009; Bystrzejewska-Piotrowska et al., 2009).

In order to overcome the above mentioned limitations, the production of the ACE-inhibitory hydrolysates was initially optimized by response surface methodology (RSM) using bromelain to determine the best conditions to produce stone fish protein hydrolysates with maximum inhibitory effects on ACE. It is hoped that improving the target activity will expand the utilization of *A. lecanora* as a bio resource abundantly available in many countries for various applications in functional foods development. The hydrolysates were then profiled and the potent ACE-inhibitory peptides present were identified. These peptides were synthesized and evaluated for their inhibitory effect against ACE.

In an attempt to improve their *in vitro* gastrointestinal stability, the bromelain-generated ACE-inhibitory stone fish-hydrolysates were encapsulated by different methods including nanoliposome formed by lipid film hydration and direct heating methods and chitosan nanoparticles fabricated via ionotropic gelation method. The chitosan nanoparticles showed higher *in vitro* gastrointestinal stability and residual ACE-inhibitory efficacy compared to nanoliposome and were selected and optimized by Box-Behnken design. The optimized chitosan nanoparticles containing the hydrolysates were characterized for physicochemical properties and then for residual ACE-inhibitory activity following their digestion under *in vitro* stimulated gastrointestinal condition. The *in vivo* antihypertensive efficacy of the nanoparticles was also evaluated on spontaneously hypertensive rats.

The selection of the chitosan as the coating material was based on a preliminary study. Chitosan have been safely used as a pH sensitive, biodegradable, biocompatible and mucoadhesive polymer in the fabrication of polymeric nanoparticles for oral-colon delivery and controlled release of bioactive peptides and proteins (Rizwan et al., 2017; Ahmed & Aljaeid et al., 2016; Luo et al., 2016). Chitosan based nanoparticles have been reported to enhance oral delivery and bioavailability of anti-cancer agent (Liang et al., 2017; Yang et al., 2017; Khedair et al., 2016; Zhang et al., 2016) and antidiabetic agent (Agrawal et al., 2015) among others. The cationic amino residues of chitosan form complex via ionic gelation with oppositely charged non-toxic polyanionic molecules, like sodium tripolyphosphate (Dambies et al., 2001). The method is simple and doesn't involve harsh treatment such as the use of organic solvents and high temperatures, hence applied for the encapsulation of fragile molecules, including peptides and proteins (Rampino et al., 2013; Al-Qadi et al., 2012; Nasti et al., 2009; Berger et al., 2004; Xu & Du, 2003).

Chitosan have been widely used as a natural polymer to improve the stability and preserve the biological efficacy of bioactive compounds. However, the biochemical and cellular toxicity of chitosan nanoparticles containing ACE-inhibitory hydrolysates/biopeptides have not been investigated. Like other polymers, the use of chitosan in the fabrication of nanoparticles for oral delivery of therapeutic agents has become a major concern about their possible tissue toxicity. The toxicity may result from direct accumulation and adverse interaction of non-biodegradable nanoparticles or due other unwanted molecules that enter the cells a long with the nanoparticles via tight junctions. Consequently, it is imperative to investigate tissue compatibility of the chitosan nanoparticles for safe therapeutic applications. Thus, acute toxicity test was carried out and the safe dose limit of the fabricated chitosan nanoparticles loaded with the ACE-inhibitory hydrolysates determined. The long term sub-acute toxicity effects of three different doses of the nanoparticles was then studied on some serum biochemical parameters and histomorphological changes on liver and kidneys of Wistar Kyoto rats.

## **1.2 Problem Statement**

Food protein derived ACE-inhibitory hydrolysates exhibit varying degree of efficacy based on the type of enzyme used in their generation. Thus, the selection of an appropriate enzyme and optimizing its condition is necessary for obtaining inhibitory hydrolysates with strong activity against ACE. Furthermore, the ACE-inhibitory hydrolysates are preferentially administered via oral route for being cheap, non-toxic and safe. However, orally administered protein hydrolysates are susceptible to degradation by gastrointestinal enzymes which decrease their bioavailability and efficacy. Hence, there is a need for the ACE-inhibitory hydrolysates to be protected via encapsulation to safeguard their structural and functional integrity for effective oral-colon delivery and biological efficacy. Moreover, in view of safety concern, the toxicity of the resulting capsule containing the ACE-inihibitory hydrolysates need to be verified especially when nanocarriers are used.

## **1.3 Objectives**

The work was designed to achieve the following objectives;

1. To optimize the production of stone fish hydrolysates with maximum ACE-inhibitory activity using bromelain
2. To profile the ACE-inhibitory hydrolysates for the identification of the potent ACE-inhibitory peptides sequences
3. To improve the stability of the ACE-inhibitory hydrolysates by nanoencapsulation
4. To evaluate the *in vivo* efficacy and toxicity effects of the nanoparticles containing the ACE-inhibitory hydrolysates on rats

## REFERENCES

- Abdal Dayem, A., Hossain, M. K., Lee, S. B., Kim, K., Saha, S. K., Yang, G. M., et al. (2017). The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles. *International Journal of Molecular Sciences*, 18(1), 120.
- Abdelhedi, O., Nasri, R., Mora, L., Jridi, M., Toldrá, F., & Nasri, M. (2018). *In silico* analysis and molecular docking study of angiotensin I-converting enzyme inhibitory peptides from smooth-hound viscera protein hydrolysates fractionated by ultrafiltration. *Food Chemistry*, 239, 453-463.
- Abdel-Wahhab, M. A., Aljawish, A., El-Nekeety, A. A., Abdel-Aiezm, S. H., Abdel-Kader, H. A., Rihn, B. H., et al. (2015). Chitosan nanoparticles and quercetin modulate gene expression and prevent the genotoxicity of aflatoxin B 1 in rat liver. *Toxicology Reports*, 2, 737-747.
- Abdel-Wahhab, M. A., Aljawish, A., El-Nekeety, A. A., Abdel-Aziem, S. H., & Hassan, N. S. (2017). Chitosan nanoparticles plus quercetin suppress the oxidative stress, modulate DNA fragmentation and gene expression in the kidney of rats fed ochratoxin A-contaminated diet. *Food and Chemical Toxicology*, 99, 209-221.
- Abdul-Hamid, A., Bakar, J., & Bee, G. H. (2002). Nutritional quality of spray dried protein hydrolysate from Black Tilapia (*Oreochromis mossambicus*). *Food Chemistry*, 78(1), 69-74.
- Abedin, M. Z., Karim, A. A., Gan, C. Y., Ghazali, F. C., Barzideh, Z., Zzaman, W., et al. (2015). Identification of angiotensin I converting enzyme inhibitory and radical scavenging bioactive peptides from sea cucumber (*Stichopus vastus*) collagen hydrolysates through optimization. *International Food Research Journal*, 22(3).
- Abul Kalam, M., Khan, A. A., Khan, S., Almalik, A., & Alshamsan, A. (2016). Optimizing indomethacin-loaded chitosan nanoparticle size, encapsulation, and release using Box–Behnken experimental design. *International Journal of Biological Macromolecules*, 87, 329-340.
- Acharya, K. R., Sturrock, E. D., Riordan, J. F., & Ehlers, M. R. (2003). ACE revisited: a new target for structure-based drug design. *Nature Reviews Drug Discovery*, 2(11), 891-902.
- Adams, M. D., Gonzalez, M. J., Miranda-Massari, J. R., Duconge, J., Rodriguez-Gomez, J. R., Berdiel, M. J., et al. (2016). An Integrative Approach to Hypertension: A Comprehensive Review of Antihypertensive Nutrients and Botanicals. *Journal of Restorative Medicine*, 5(1), 57-73.



- Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009). Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. *Advanced Drug Delivery Reviews*, 61(6), 428-437.
- Agrawal, A. K., Harde, H., Thanki, K., & Jain, S. (2013). Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. *Biomacromolecules*, 15(1), 350-360.
- Agrawal, A. K., Urimi, D., Harde, H., Kushwah, V., & Jain, S. (2015). Folate appended chitosan nanoparticles augment the stability, bioavailability and efficacy of insulin in diabetic rats following oral administration. *RSC Advances*, 5(127), 105179-105193.
- Ahmed, T. A., & Aljaeid, B. M. (2016). Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. *Drug Design, Development and Therapy*, 10, 483.
- Ahn, C. B., Jeon, Y. J., Kim, Y. T., & Je, J. Y. (2012). Angiotensin I converting enzyme (ACE) inhibitory peptides from salmon byproduct protein hydrolysate by Alcalase hydrolysis. *Process Biochemistry*, 47(12), 2240-2245.
- Ahn, J. H., Kim, Y. P., Lee, Y. M., Seo, E. M., Lee, K. W., & Kim, H. S. (2008). Optimization of microencapsulation of seed oil by response surface methodology. *Food Chemistry*, 107(1), 98-105.
- Ajdari, M., & Ghahnavieh, M. Z. (2014). Histopathology effects of nickel nanoparticles on lungs, liver, and spleen tissues in male mice. *International Nano Letters*, 4(3), 113.
- Alam, M. S., Garg, A., Pottoo, F. H., Saifullah, M. K., Tareq, A. I., Manzoor, O., et al. (2017). Gum ghatti mediated, one pot green synthesis of optimized Gold nanoparticles: Investigation of process-variables impact using Box-Behnken based statistical design. *International Journal of Biological Macromolecules*.
- Alemán, A., Giménez, B., Pérez-Santin, E., Gómez-Guillén, M. C., & Montero, P. (2011). Contribution of Leu and Hyp residues to antioxidant and ACE-inhibitory activities of peptide sequences isolated from squid gelatin hydrolysate. *Food Chemistry*, 125(2), 334-341.
- Al-Qadi, S., Grenha, A., Carrión-Recio, D., Seijo, B., & Remuñán-López, C. (2012). Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. *Journal of Controlled Release*, 157(3), 383-390.

- Althunibat, O. Y., Hashim, R. B., Taher, M., Daud, J. M., Ikeda, M. A., & Zali, B. I. (2009). In vitro antioxidant and antiproliferative activities of three Malaysian sea cucumber species. *European Journal of Scientific Research*, 37(3), 376-87.
- Amado, I. R., Vázquez, J. A., González, P., Esteban-Fernández, D., Carrera, M., & Piñeiro, C. (2014). Identification of the major ACE-inhibitory peptides produced by enzymatic hydrolysis of a protein concentrate from cuttlefish wastewater. *Marine Drugs*, 12(3), 1390-1405.
- Anwar M., Abdelhalim, K., & Jarrar, B. M. (2012). Histological alterations in the liver of rats induced by different gold nanoparticle sizes, doses and exposure duration. *Journal of Nanobiotechnology*, 10(1), 5.
- Aragao-Santiago, L., Hillaireau, H., Grabowski, N., Mura, S., Nascimento, T. L., Dufort, S., et al. (2016). Compared *in vivo* toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles. *Nanotoxicology*, 10(3), 292-302.
- Ariyoshi, Y. (1993). Angiotensin-converting enzyme inhibitors derived from food proteins. *Trends in Food Science & Technology*, 4(5), 139-144.
- Asoodeh, A., Homayouni-Tabrizi, M., Shabestarian, H., Emtenani, S., & Emtenani, S. (2016). Biochemical characterization of a novel antioxidant and angiotensin I-converting enzyme inhibitory peptide from *Struthio camelus* egg white protein hydrolysis. *Journal of Food and Drug Analysis*, 24(2), 332-342.
- Assadpour, E., Maghsoudlou, Y., Jafari, S. M., Ghorbani, M., & Aalami, M. (2016). Optimization of folic acid nano-emulsification and encapsulation by maltodextrin-whey protein double emulsions. *International Journal of Biological Macromolecules*, 86, 197-207.
- Asselbergs, F. W., van der Harst, P., Jessurun, G. A., Tio, R. A., & van Gilst, W. H. (2005). Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. *Vascular Pharmacology*, 42(3), 125-140.
- Association of Official Analytical Chemists (2005). *Official Methods of Analysis*, 18th ed.; Association of Official Analytical Chemists: Washington, DC, USA.
- Aydın, M., Sevgili, H., Tufan, B., Emre, Y., & Köse, S. (2011). Proximate composition and fatty acid profile of three different fresh and dried commercial sea cucumbers from Turkey. *International Journal of Food Science & Technology*, 46(3), 500-508.

- Badawi, A. A., El-Laithy, H. M., El Qidra, R. K., & El Mofty, H. (2008). Chitosan based nanocarriers for indomethacin ocular delivery. *Archives of Pharmacal Research*, 31(8), 1040.
- Balti, R., Bougateg, A., Sila, A., Guillochon, D., Dhulster, P., & Nedjar-Arroume, N. (2015). Nine novel angiotensin I-converting enzyme (ACE) inhibitory peptides from cuttlefish (*Sepia officinalis*) muscle protein hydrolysates and antihypertensive effect of the potent active peptide in spontaneously hypertensive rats. *Food Chemistry*, 170, 519-525.
- Balti, R., Nedjar-Arroume, N., Adjé, E. Y., Guillochon, D., & Nasri, M. (2010). Analysis of novel angiotensin I-converting enzyme inhibitory peptides from enzymatic hydrolysates of cuttlefish (*Sepia officinalis*) muscle proteins. *Journal of Agricultural and Food Chemistry*, 58(6), 3840-3846.
- Banga, A. K. (2015). *Therapeutic peptides and proteins: Formulation, processing, and delivery systems*. CRC press.
- Barbana, C., & Boye, J. I. (2011). Angiotensin I-converting enzyme inhibitory properties of lentil protein hydrolysates: Determination of the kinetics of inhibition. *Food Chemistry*, 127(1), 94-101.
- Barbosa, C., Morais, H. A., Delvivo, F. M., Mansur, H. S., De Oliveira, M. C., & Silvestre, M. P. (2004). Papain hydrolysates of casein: molecular weight profile and encapsulation in lipospheres. *Journal of the Science of Food and Agriculture*, 84(14), 1891-1900.
- Beltrán-Barrientos, L. M., Hernández-Mendoza, A., Torres-Llenez, M. J., González-Córdova, A. F., & Vallejo-Córdoba, B. (2016). Invited review: Fermented milk as antihypertensive functional food. *Journal of Dairy Science*, 99(6), 4099-4110.
- Ben-Slama, I., Mrad, I., Rihane, N., Mir, L. E., Sakly, M., & Amara, S. (2015). Sub-acute oral toxicity of zinc oxide nanoparticles in male rats. *Journal of Nanomedicine & Nanotechnology*, 6(3), 1.
- Berger, J., Reist, M., Mayer, J. M., Felt, O., Peppas, N. A., & Gurny, R. (2004). Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. *European Journal of Pharmaceutics and Biopharmaceutics*, 57(1), 19-34.
- Bezerra, M. A., Santelli, R. E., Oliveira, E. P., Villar, L. S., & Escaleira, L. A. (2008). Response surface methodology (RSM) as a tool for optimization in analytical chemistry. *Talanta*, 76(5), 965-977.
- Bordbar, S., Anwar, F., & Saari, N. (2011). High-value components and bioactives from sea cucumbers for functional foods—a review. *Marine Drugs*, 9(10), 1761-1805.

- Bordbar, S., Ebrahimpour, A., Abdul Hamid, A., Abdul Manap, M. Y., Anwar, F., & Saari, N. (2013). The improvement of the endogenous antioxidant property of stone fish (*Actinopyga lecanora*) tissue using enzymatic proteolysis. *BioMed research international*, 2013.
- Box, G. E., & Behnken, D. W. (1960). Some new three level designs for the study of quantitative variables. *Technometrics*, 2(4), 455-475.
- Box, G. E., & Wilson, K. (1951). On the experimental attainment of optimum conditions. *Journal of the Royal Statistical Society. Series B (Methodological)*, 13(1), 1-45.
- Bruckner, A. W., Johnson, K. A., & Field, J. D. (2003). Conservation strategies for sea cucumbers: Can a CITES Appendix II listing promote sustainable international trade. *SPC Bêche-de-mer Information Bulletin*, 18, 24-33.
- Bueno-Solano, C., López-Cervantes, J., Campas-Baypoli, O. N., Lauterio-García, R., Adan-Bante, N. P., & Sánchez-Machado, D. I. (2009). Chemical and biological characteristics of protein hydrolysates from fermented shrimp by-products. *Food Chemistry*, 112(3), 671-675.
- Bystrzejewska-Piotrowska, G., Golimowski, J., & Urban, P. L. (2009). Nanoparticles: their potential toxicity, waste and environmental management. *Waste Management*, 29(9), 2587-2595.
- Byun, H. G., & Kim, S. K. (2001). Purification and characterization of angiotensin I converting enzyme (ACE) inhibitory peptides from Alaska pollack (*Theragra chalcogramma*) skin. *Process Biochemistry*, 36(12), 1155-1162.
- Byun, H. G., & Kim, S. K. (2002). Structure and activity of angiotensin I converting enzyme inhibitory peptides derived from Alaskan pollack skin. *BMB Reports*, 35(2), 239-243.
- Cao, W., Zhang, C., Hong, P., Ji, H., & Hao, J. (2010). Purification and identification of an ACE inhibitory peptide from the peptic hydrolysate of *Acetes chinensis* and its antihypertensive effects in spontaneously hypertensive rats. *International Journal of Food Science & Technology*, 45(5), 959-965.
- Cao, W., Zhang, C., Ji, H., & Hao, J. (2012). Optimization of peptic hydrolysis parameters for the production of angiotensin I- converting enzyme inhibitory hydrolysate from *Acetes chinensis* through Plackett–Burman and response surface methodological approaches. *Journal of the Science of Food and Agriculture*, 92(1), 42-48.
- Chakrabarti, S., Jahandideh, F., & Wu, J. (2014). Food-derived bioactive peptides on inflammation and oxidative stress. *BioMed Research International*, 2014.

- Chen, D., Disotuar, M. M., Xiong, X., Wang, Y., & Chou, D. H. C. (2017). Selective N-terminal functionalization of native peptides and proteins. *Chemical Science*, 8(4), 2717-2722.
- Chen, J. (2003). Overview of sea cucumber farming and sea ranching practices in China. *SPC beche-de-mer Information Bulletin*, 18, 18-23.
- Chen, K. N., Chen, M. J., & Lin, C. W. (2006). Optimal combination of the encapsulating materials for probiotic microcapsules and its experimental verification (R1). *Journal of Food Engineering*, 76(3), 313-320.
- Chen, K. N., Chen, M. J., Liu, J. R., Lin, C. W., & Chiu, H. Y. (2005). Optimization of incorporated prebiotics as coating materials for probiotic microencapsulation. *Journal of Food Science*, 70(5).
- Chen, S., Xue, C., Tang, Q., Yu, G., & Chai, W. (2011). Comparison of structures and anticoagulant activities of fucosylated chondroitin sulfates from different sea cucumbers. *Carbohydrate Polymers*, 83(2), 688-696.
- Cheison, S. C., Wang, Z., & Xu, S. Y. (2007). Use of response surface methodology to optimise the hydrolysis of whey protein isolate in a tangential flow filter membrane reactor. *Journal of Food Engineering*, 80(4), 1134-1145.
- Chen, T. L., Lo, Y. C., Hu, W. T., Wu, M. C., Chen, S. T., & Chang, H. M. (2003). Microencapsulation and modification of synthetic peptides of food proteins reduces the blood pressure of spontaneously hypertensive rats. *Journal of Agricultural and Food Chemistry*, 51(6), 1671-1675.
- Cheung, H. S., Wang, F. L., Ondetti, M. A., Sabo, E. F., & Cushman, D. W. (1980). Binding of peptide substrates and inhibitors of angiotensin-converting enzyme. Importance of the COOH-terminal dipeptide sequence. *Journal of Biological Chemistry*, 255(2), 401-407.
- Cheung, R. C. F., Ng, T. B., Wong, J. H., & Chan, W. Y. (2015). Chitosan: an update on potential biomedical and pharmaceutical applications. *Marine Drugs*, 13(8), 5156-5186.
- Cheung, R. C. F., Ng, T. B., Wong, J. H., & Chan, W. Y. (2015). Chitosan: an update on potential biomedical and pharmaceutical applications. *Marine Drugs*, 13(8), 5156-5186.
- Chinde, S., Dumala, N., Rahman, M. F., Kamal, S. S. K., Kumari, S. I., Mahboob, M., et al. (2017). Toxicological assessment of tungsten oxide nanoparticles in rats after acute oral exposure. *Environmental Science and Pollution Research*, 1-18.

- Chung, H. E., Yu, J., Baek, M., Lee, J. A., Kim, M. S., Kim, S. H., et al. (2013). Toxicokinetics of zinc oxide nanoparticles in rats. In *Journal of Physics: Conference Series*(Vol. 429, No. 1, p. 012037). IOP Publishing.
- Cinq-Mars, C. D., & Li-Chan, E. C. (2007). Optimizing angiotensin I-converting enzyme inhibitory activity of Pacific hake (*Merluccius productus*) fillet hydrolysate using response surface methodology and ultrafiltration. *Journal of Agricultural and Food Chemistry*, 55(23), 9380-9388.
- Collin, P. D. (2004). Peptides having anti-cancer and anti-inflammatory activity, *U.S. Patent No. 6,767,890*. Washington, DC: U.S. Patent and Trademark Office, 6, 767,890, 27.
- Collin, P. D. (1999). Process for obtaining medically active fractions from sea cucumber. *U.S. Patent No. 5,876,762*. Washington, DC: U.S. Patent and Trademark Office.
- Conand, C., Gamboa, R. & Purcell, S. 2013. *Actinopyga lecanora*. *The IUCN Red List of Threatened Species 2013*: e.T180266A1608301. <http://dx.doi.org/10.2305/IUCN.UK.2013-1.RLTS.T180266A1608301.en>
- Cui, J., Li, C., Guo, W., Li, Y., Wang, C., Zhang, L., et al. (2007). Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?. *Journal of Controlled Release*, 118(2), 204-215.
- Cushman, D. W., & Cheung, H. S. (1971). Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. *Biochemical pharmacology*, 20(7), 1637-1648.
- da Rosa Zavareze, E., Telles, A. C., El Halal, S. L. M., da Rocha, M., Colussi, R., de Assis, L. M., et al. (2014). Production and characterization of encapsulated antioxidative protein hydrolysates from Whitemouth croaker (*Micropogonias furnieri*) muscle and byproduct. *LWT-Food Science and Technology*, 59(2), 841-848.
- da Silva Malheiros, P., Micheletto, Y. M. S., da Silveira, N. P., & Brandelli, A. (2010). Development and characterization of phosphatidylcholine nanovesicles containing the antimicrobial peptide nisin. *Food Research International*, 43(4), 1198-1203.
- Dambies, L., Vincent, T., Domard, A., & Guibal, E. (2001). Preparation of chitosan gel beads by ionotropic molybdate gelation. *Biomacromolecules*, 2(4), 1198-1205.
- Daskaya-Dikmen, C., Yucetepe, A., Karbancioglu-Guler, F., Daskaya, H., & Ozcelik, B. (2017). Angiotensin-I-Converting Enzyme (ACE)-Inhibitory Peptides from Plants. *Nutrients*, 9(4), 316.

- Dean, A. M., & Voss, D. (1999). *Design and analysis of experiments* (Vol. 1). New York: Springer.
- Deddish, P. A., Wang, J., Michel, B., Morris, P. W., Davidson, N. O., Skidgel, R. A., et al. (1994). Naturally occurring active N-domain of human angiotensin I-converting enzyme. *Proceedings of the National Academy of Sciences*, *91*(16), 7807-7811.
- Dutta, P. K., Dutta, J., & Tripathi, V. S. (2004). Chitin and chitosan: Chemistry, properties and applications.
- EFSA Panel on Dietetic Products, N. a. A. (2010). Scientific opinion on the safety of “sardine peptide product” as a novel food ingredient. *EFSA Journal* *8*, 1684–1700.
- Ehlers, M. R. (2006). Safety issues associated with the use of angiotensin-converting enzyme inhibitors: Response to: BELTRAMI L, ZINGALE LC, CARUGO S, CICARDI M: Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it. *Expert Opinion on Drug Safety*, *5*(6), 739-740.
- Elbl, G., & Wagner, H. (1991). A new method for the in vitro screening of inhibitors of angiotensin-converting enzyme (ACE), using the chromophore-and fluorophore-labelled substrate, dansyltriglycine. *Planta Medica*, *57*(02), 137-141.
- El-Denshary, E. S., Aljawish, A., El-Nekeety, A. A., Hassan, N. S., Saleh, R. H., Rihn, B. H., et al. (2015). Possible synergistic effect and antioxidant properties of chitosan nanoparticles and quercetin against carbon tetrachloride-induce hepatotoxicity in rats. *Soft Nanoscience Letters*, *5*(02), 36.
- Enari, H., Takahashi, Y., & Kawarasaki, M. (2007). Anti-hypertensive effect and safety of long-term intake of a drink containing salmon peptide-A randomized, double-blind, placebo-controlled trial. *Japanese Pharmacology and Therapeutics*, *35*(12), 1261-1277.
- Enari, H., Takahashi, Y., Kawarasaki, M., Tada, M., & Tatsuta, K. (2008). Identification of angiotensin I-converting enzyme inhibitory peptides derived from salmon muscle and their antihypertensive effect. *Fisheries Science*, *74*(4), 911-920.
- Ezhilarasi, P. N., Karthik, P., Chhanwal, N., & Anandharamakrishnan, C. (2013). Nanoencapsulation techniques for food bioactive components: a review. *Food and Bioprocess Technology*, *6*(3), 628-647.

- Fahmi, A., Morimura, S., Guo, H. C., Shigematsu, T., Kida, K., & Uemura, Y. (2004). Production of angiotensin I converting enzyme inhibitory peptides from sea bream scales. *Process Biochemistry*, 39(10), 1195-1200.
- Fathi, M., Martín, Á., & McClements, D. J. (2014). Nanoencapsulation of food ingredients using carbohydrate based delivery systems. *Trends in Food Science & Technology*, 39(1), 18-39.
- Fathi, M., Mozafari, M. R., & Mohebbi, M. (2012). Nanoencapsulation of food ingredients using lipid based delivery systems. *Trends in Food Science & Technology*, 23(1), 13-27.
- Favaro-Trindade, C. S., Santana, A. S., Monterrey-Quintero, E. S., Trindade, M. A., & Netto, F. M. (2010). The use of spray drying technology to reduce bitter taste of casein hydrolysate. *Food Hydrocolloids*, 24(4), 336-340.
- Fitzgerald, C., Mora-Soler, L., Gallagher, E., O'Connor, P., Prieto, J., Soler-Vila, A., et al. (2012). Isolation and characterization of bioactive pro-peptides with in vitro renin inhibitory activities from the macroalga *Palmaria palmata*. *Journal of Agricultural and Food Chemistry*, 60(30), 7421-7427.
- FitzGerald, R. J., & Meisel, H. (2000). Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. *British Journal of Nutrition*, 84(S1), 33-37.
- FitzGerald, R. J., Murray, B. A., & Walsh, D. J. (2004). Hypotensive peptides from milk proteins. *The Journal of Nutrition*, 134(4), 980S-988S.
- Foltz, M., Van Buren, L., Klaffke, W., & Duchateau, G. S. (2009). Modeling of the relationship between dipeptide structure and dipeptide stability, permeability, and ACE inhibitory activity. *Journal of Food Science*, 74(7).
- Forghani, B., Zarei, M., Ebrahimpour, A., Philip, R., Bakar, J., Hamid, A. A., et al. (2016). Purification and characterization of angiotensin converting enzyme-inhibitory peptides derived from *Stichopus horrens*: Stability study against the ACE and inhibition kinetics. *Journal of Functional Foods*, 20, 276-290.
- Fredalina, B. D., Ridzwan, B. H., Abidin, A. Z., Kaswandi, M. A., Zaiton, H., Zali, I., et al. (1999). Fatty acid compositions in local sea cucumber. *General Pharmacology: The Vascular System*, 33(4), 337-340.
- Fujita, H., & Yoshikawa, M. (1999). LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. *Immunopharmacology*, 44(1), 123-127.
- Fujita, H., Yamagami, T., & Ohshima, K. (2001). Effects of an ACE-inhibitory agent, katsuobushi oligopeptide, in the spontaneously hypertensive rat and in borderline and mildly hypertensive subjects. *Nutrition Research*, 21(8), 1149-1158.



- Fujita, H., Yokoyama, K., Yasumoto, R., & Yoshikawa, M. (1995). Antihypertensive effect of thermolysin digest of dried bonito in spontaneously hypertensive rat. *Clinical and Experimental Pharmacology and Physiology*, 22(s1).
- Fujita, N., & Yoshikawa, M. (2008). Marine-derived protein hydrolysates, their biological activities and potential as functional food ingredients: ACE-inhibitory peptides derived from bonito. *Marine Nutraceuticals and Functional Foods*, 247-258.
- Geng, X., Tian, G., Zhang, W., Zhao, Y., Zhao, L., Wang, H., et al. (2016). A Tricholoma matsutake peptide with angiotensin converting enzyme inhibitory and antioxidative activities and antihypertensive effects in spontaneously hypertensive rats. *Scientific Reports*, 6.
- Georgiadis, D., Beau, F., Czarny, B., Cotton, J., Yiotakis, A., & Dive, V. (2003). Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin. *Circulation Research*, 93(2), 148-154.
- Gerloff, K., Albrecht, C., Boots, A. W., Förster, I., & Schins, R. P. (2009). Cytotoxicity and oxidative DNA damage by nanoparticles in human intestinal Caco-2 cells. *Nanotoxicology*, 3(4), 355-364.
- Ghanbari, R., Ebrahimpour, A., Abdul-Hamid, A., Ismail, A., & Saari, N. (2012). *Actinopyga lecanora* hydrolysates as natural antibacterial agents. *International Journal of Molecular Sciences*, 13(12), 16796-16811.
- Ghanbari, R., Zarei, M., Ebrahimpour, A., Abdul-Hamid, A., Ismail, A., & Saari, N. (2015). Angiotensin-I converting enzyme (ACE) inhibitory and anti-oxidant activities of sea cucumber (*Actinopyga lecanora*) hydrolysates. *International Journal of Molecular Sciences*, 16(12), 28870-28885.
- Ghassem, M., Arihara, K., Babji, A. S., Said, M., & Ibrahim, S. (2011). Purification and identification of ACE inhibitory peptides from Haruan (*Channa striatus*) myofibrillar protein hydrolysate using HPLC–ESI-TOF MS/MS. *Food Chemistry*, 129(4), 1770-1777.
- Ghassem, M., Babji, A. S., Said, M., Mahmoodani, F., & Arihara, K. (2014). Angiotensin I-converting enzyme inhibitory peptides from snakehead fish sarcoplasmic protein hydrolysate. *Journal of Food Biochemistry*, 38(2), 140-149.
- Ghorbannezhad, P., Bay, A., Yolmeh, M., Yadollahi, R., & Moghadam, J. Y. (2016). Optimization of coagulation–flocculation process for medium density fiberboard (MDF) wastewater through response surface methodology. *Desalination and Water Treatment*, 57(56), 26916-26931.

- Gildberg, A., Arnesen, J. A., Sæther, B. S., Rauø, J., & Stenberg, E. (2011). Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (*Pandalus borealis*) and identification of two novel inhibitory tri-peptides. *Process Biochemistry*, *46*(11), 2205-2209.
- Girgih, A. T., Nwachukwu, I. D., Hasan, F. M., Fagbemi, T. N., Malomo, S. A., Gill, T. A., et al. (2016). Kinetics of in vitro enzyme inhibition and blood pressure-lowering effects of salmon (*Salmo salar*) protein hydrolysates in spontaneously hypertensive rats. *Journal of Functional Foods*, *20*, 43-53.
- Go, A.S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., et al. (2013). Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association; Department of Health and Human Services: Washington, DC, USA, Volume 127.
- Goad, L. J., Garneau, F. X., Simard, J. L., ApSimon, J. W., & Girard, M. (1985). Isolation of  $\Delta^9$  (11)-sterols from the sea cucumber *psolusfabricii*. Implications for holothurin biosynthesis. *Tetrahedron Letters*, *26*(29), 3513-3516.
- Gong, K. J., Shi, A. M., Liu, H. Z., Liu, L., Hu, H., Yang, Y., et al. (2016). Preparation of nanoliposome loaded with peanut peptide fraction: stability and bioavailability. *Food & Function*, *7*(4), 2034-2042.
- Goudarzi, M., Madadlou, A., Mousavi, M. E., & Emam-Djomeh, Z. (2012). Optimized preparation of ACE-inhibitory and antioxidative whey protein hydrolysate using response surface method. *Dairy Science & Technology*, *92*(6), 641-653.
- Grimble, G. K., Keohane, P. P., Higgins, B. E., Kaminski, M. V., & Silk, D. B. A. (1986). Effect of peptide chain length on amino acid and nitrogen absorption from two lactalbumin hydrolysates in the normal human jejunum. *Clinical Science*, *71*(1), 65-69.
- Gu, R. Z., Li, C. Y., Liu, W. Y., Yi, W. X., & Cai, M. Y. (2011). Angiotensin I-converting enzyme inhibitory activity of low-molecular-weight peptides from Atlantic salmon (*Salmo salar* L.) skin. *Food Research International*, *44*(5), 1536-1540.
- Guo, Y., Pan, D., & Tanokura, M. (2009). Optimisation of hydrolysis conditions for the production of the angiotensin-I converting enzyme (ACE) inhibitory peptides from whey protein using response surface methodology. *Food Chemistry*, *114*(1), 328-333.
- Gupta, S., Jain, A., Chakraborty, M., Sahni, J. K., Ali, J., & Dang, S. (2013). Oral delivery of therapeutic proteins and peptides: a review on recent developments. *Drug Delivery*, *20*(6), 237-246.

- Hai- Lun, H. E., Xiu- Lan, C., Cai- Yun, S., Yu- Zhong, Z., & Bai- Cheng, Z. (2006). Analysis of novel angiotensin- I- converting enzyme inhibitory peptides from protease- hydrolyzed marine shrimp *Acetes chinensis*. *Journal of Peptide Science*, 12(11), 726-733.
- Hanafy, A. S., Farid, R. M., Helmy, M. W., & ElGamal, S. S. (2016). Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management. *Drug Delivery*, 23(8), 3111-3122.
- Harnedy, P. A., & FitzGerald, R. J. (2012). Bioactive peptides from marine processing waste and shellfish: A review. *Journal of Functional Foods*, 4(1), 6-24.
- Harris, J. M., & Chess, R. B. (2003). Effect of pegylation on pharmaceuticals. *Nature Reviews Drug Discovery*, 2(3), 214-221.
- Hartmann, R., & Meisel, H. (2007). Food-derived peptides with biological activity: from research to food applications. *Current Opinion in Biotechnology*, 18(2), 163-169.
- Hattori, Y., & Hashida, M. (2005). Evaluation of size and zeta potential of DNA/carrier complexes. *Non-viral Gene Therapy*. Springer, Tokyo, 293-299.
- He, C., Yin, L., Tang, C., & Yin, C. (2012). Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. *Biomaterials*, 33(33), 8569-8578.
- He, R., Aluko, R. E., & Ju, X. R. (2014). Evaluating molecular mechanism of hypotensive peptides interactions with renin and angiotensin converting enzyme. *PloS One*, 9(3), e91051.
- He, R., Ma, H., Zhao, W., Qu, W., Zhao, J., Luo, L., et al. (2012). Modeling the QSAR of ACE-inhibitory peptides with ANN and its applied illustration. *International Journal of Peptides*, 2012.
- Hernández-Ledesma, B., del Mar Contreras, M., & Recio, I. (2011). Antihypertensive peptides: production, bioavailability and incorporation into foods. *Advances in Colloid and Interface Science*, 165(1), 23-35.
- Himaya, S. W. A., Ngo, D. H., Ryu, B., & Kim, S. K. (2012). An active peptide purified from gastrointestinal enzyme hydrolysate of Pacific cod skin gelatin attenuates angiotensin-1 converting enzyme (ACE) activity and cellular oxidative stress. *Food Chemistry*, 132(4), 1872-1882.
- Hing, H. L., Kaswandi, M. A., Azraul-Mumtazah, R., Hamidah, S. A., Sahalan, A. Z., Normalawati, S., et al. (2007). Effect of methanol extracts from sea

cucumbers *Holothuria edulis* and *Stichopus chloronotus* on *Candida albicans*. *Microscopy and Microanalysis*, 13, 270-271.

- Holmquist, B., Bünning, P., & Riordan, J. F. (1979). A continuous spectrophotometric assay for angiotensin converting enzyme. *Analytical Biochemistry*, 95(2), 540-548.
- Hong, F., Ming, L., Yi, S., Zhanxia, L., Yongquan, W., & Chi, L. (2008). The antihypertensive effect of peptides: a novel alternative to drugs?. *Peptides*, 29(6), 1062-1071.
- Huynh, T. V., Caffin, N., Dykes, G. A., & Bhandari, B. (2008). Optimization of the microencapsulation of lemon myrtle oil using response surface methodology. *Drying Technology*, 26(3), 357-368.
- Ibrahim, H. R., Ahmed, A. S., & Miyata, T. (2017). Novel angiotensin-converting enzyme inhibitory peptides from caseins and whey proteins of goat milk. *Journal of Advanced Research*, 8(1), 63-71.
- Ichimura, T., Hu, J., Aita, D. Q., & Maruyama, S. (2003). Angiotensin I-converting enzyme inhibitory activity and insulin secretion stimulative activity of fermented fish sauce. *Journal of Bioscience and Bioengineering*, 96(5), 496-499.
- Inagami, T. (1994). The renin-angiotensin system. *Essays in biochemistry*, 28, 147-164.
- Intarasirisawat, R., Benjakul, S., Wu, J., & Visessanguan, W. (2013). Isolation of antioxidative and ACE inhibitory peptides from protein hydrolysate of skipjack (*Katsuwana pelamis*) roe. *Journal of Functional Foods*, 5(4), 1854-1862.
- Iroyukifujita, H., Eiichiyokoyama, K., & Yoshikawa, M. (2000). Classification and Antihypertensive Activity of Angiotensin I- Converting Enzyme Inhibitory Peptides Derived from Food Proteins. *Journal of Food Science*, 65(4), 564-569.
- Iwaniak, A., Minkiewicz, P., & Darewicz, M. (2014). Food- originating ACE inhibitors, including antihypertensive peptides, as preventive food components in blood pressure reduction. *Comprehensive Reviews in Food Science and Food Safety*, 13(2), 114-134.
- Jafari, S. M., Assadpoor, E., He, Y., & Bhandari, B. (2008). Encapsulation efficiency of food flavours and oils during spray drying. *Drying Technology*, 26(7), 816-835.
- Jain, S., Patil, S. R., Swarnakar, N. K., & Agrawal, A. K. (2012). Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). *Molecular Pharmaceutics*, 9(9), 2626-2635.

- Jamdar, S. N., Rajalakshmi, V., Pednekar, M. D., Juan, F., Yardi, V., & Sharma, A. (2010). Influence of degree of hydrolysis on functional properties, antioxidant activity and ACE inhibitory activity of peanut protein hydrolysate. *Food Chemistry*, 121(1), 178-184.
- Jao, C. L., Huang, S. L., & Hsu, K. C. (2012). Angiotensin I-converting enzyme inhibitory peptides: inhibition mode, bioavailability, and antihypertensive effects. *BioMedicine*, 2(4), 130-136.
- Jarudilokkul, S., Tongthammachat, A., & Boonamnuayvittaya, V. (2011). Preparation of chitosan nanoparticles for encapsulation and release of protein. *Korean Journal of Chemical Engineering*, 28(5), 1247.
- Je, J. Y., Park, P. J., Byun, H. G., Jung, W. K., & Kim, S. K. (2005). Angiotensin I converting enzyme (ACE) inhibitory peptide derived from the sauce of fermented blue mussel, *Mytilus edulis*. *Bioresource Technology*, 96(14), 1624-1629.
- Jeng, H. A., & Swanson, J. (2006). Toxicity of metal oxide nanoparticles in mammalian cells. *Journal of Environmental Science and Health Part A*, 41(12), 2699-2711.
- Jimsheena, V. K., & Gowda, L. R. (2009). Colorimetric, high-throughput assay for screening angiotensin I-converting enzyme inhibitors. *Analytical Chemistry*, 81(22), 9388-9394.
- Jun, S. Y., Park, P. J., Jung, W. K., & Kim, S. K. (2004). Purification and characterization of an antioxidative peptide from enzymatic hydrolysate of yellowfin sole (*Limanda aspera*) frame protein. *European Food Research and Technology*, 219(1), 20-26.
- Jung, E., Kim, J., Kim, M., Jung, D. H., Rhee, H., Shin, J. M., et al. (2007). Artificial neural network models for prediction of intestinal permeability of oligopeptides. *BMC Bioinformatics*, 8(1), 245.
- Jung, W. K., Mendis, E., Je, J. Y., Park, P. J., Son, B. W., Kim, H. C., et al. (2006). Angiotensin I-converting enzyme inhibitory peptide from yellowfin sole (*Limanda aspera*) frame protein and its antihypertensive effect in spontaneously hypertensive rats. *Food Chemistry*, 94(1), 26-32.
- Jyh-Sheng, H., Yu-Ling, T., & Kuo-Chiang, H. (2010). The feasibility of antihypertensive oligopeptides encapsulated in liposomes prepared with phytosterols-b-sitosterol or stigmasterol. *Food Research International*, 43, 133-139.
- Kajimoto, O. (2004). Hypotensive effect and safety of the granular foods containing oligo peptides derived from nori (*Porphyra yezoensis*) in subjects with high-normal blood pressure. *Journal of Nutrition & Food Sciences*, 7, 43-58.

- Kajimoto, O., Nkano, T., Hahara, T., Kajimoto, Y., & Takahasi, T. (2002). Hypotensive effects of brown alga peptides containing jelly on mild hypertensive subjects. *Journal of Nutrition & Food Sciences*, 5, 67-81.
- Kamath, V., Niketh, S., Chandrashekar, A., & Rajini, P. S. (2006). Chymotryptic hydrolysates of a-kafirin, the storage protein of sorghum (*Sorghum bicolor*) exhibited angiotensin converting enzyme inhibitory activity. *Food Chemistry*, 100(1), 306-311.
- Kanbargi, K. D., Sonawane, S. K., & Arya, S. S. (2017). Encapsulation characteristics of protein hydrolysate extracted from *Ziziphus jujube* seed. *International Journal of Food Properties*, 1-10.
- Kawamura, Y., Takane, T., Satake, M., & Sugimoto, T. (1992). Physiologically active peptide motif in proteins: Peptide inhibitors of ACE from the hydrolysates of Antarctic krill muscle protein. *JARQ: Japan Agricultural Research Quarterly (Japan)*.
- Kawasaki, T., Seki, E., Osajima, K., Yoshida, M., Asada, K., Matsui, T., et al. (2000). Antihypertensive effect of valyl-tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on mild hypertensive subjects. *Journal of Human Hypertension*, 14(8), 519.
- Kerr, R. G., & Chen, Z. (1995). *In vivo* and *in vitro* biosynthesis of saponins in sea cucumbers. *Journal of Natural Products*, 58(2), 172-176.
- Khanna, P., Ong, C., Bay, B. H., & Baeg, G. H. (2015). Nanotoxicity: an interplay of oxidative stress, inflammation and cell death. *Nanomaterials*, 5(3), 1163-1180.
- Kha, T. C., Nguyen, M. H., Roach, P. D., & Stathopoulos, C. E. (2014). Microencapsulation of gac oil by spray drying: optimization of wall material concentration and oil load using response surface methodology. *Drying Technology*, 32(4), 385-397.
- Khdair, A., Hamad, I., Alkhatib, H., Bustanji, Y., Mohammad, M., Tayem, R., et al. (2016). Modified-chitosan nanoparticles: Novel drug delivery systems improve oral bioavailability of doxorubicin. *European Journal of Pharmaceutical Sciences*, 93, 38-44.
- Kim, S. K. (Ed.). (2013). *Marine proteins and peptides: biological activities and applications*. John Wiley & Sons.
- Kim, S. K., & Himaya, S. W. A. (2013). Edible Marine Invertebrates. *Marine Nutraceuticals: Prospects and Perspectives*, 243.

- Kim, S. K., & Rajapakse, N. (2005). Enzymatic production and biological activities of chitosan oligosaccharides (COS): A review. *Carbohydrate Polymers*, 62(4), 357-368.
- Kim, S. K., Byun, H. G., Park, P. J., & Shahidi, F. (2001). Angiotensin I converting enzyme inhibitory peptides purified from bovine skin gelatin hydrolysate. *Journal of Agricultural and Food Chemistry*, 49(6), 2992-2997.
- Ko, J. W., Hong, E. T., Lee, I. C., Park, S. H., Park, J. I., Seong, N. W., et al. (2015). Evaluation of 2-week repeated oral dose toxicity of 100 nm zinc oxide nanoparticles in rats. *Laboratory Animal Research*, 31(3), 139-147.
- Ko, S. C., Kang, N., Kim, E. A., Kang, M. C., Lee, S. H., Kang, S. M., et al. (2012b). A novel angiotensin I-converting enzyme (ACE) inhibitory peptide from a marine *Chlorella ellipsoidea* and its antihypertensive effect in spontaneously hypertensive rats. *Process Biochemistry*, 47(12), 2005-2011.
- Ko, S. C., Lee, J. K., Byun, H. G., Lee, S. C., & Jeon, Y. J. (2012a). Purification and characterization of angiotensin I-converting enzyme inhibitory peptide from enzymatic hydrolysates of *Styela clava* flesh tissue. *Process Biochemistry*, 47(1), 34-40.
- Kong, B., & Xiong, Y. L. (2006). Antioxidant activity of zein hydrolysates in a liposome system and the possible mode of action. *Journal of Agricultural and Food Chemistry*, 54(16), 6059-6068.
- Kontis, V., Mathers, C. D., Rehm, J., Stevens, G. A., Shield, K. D., Bonita, R., et al. (2014). Contribution of six risk factors to achieving the 25× 25 non-communicable disease mortality reduction target: a modelling study. *The Lancet*, 384(9941), 427-437.
- Korhonen, H., & Pihlanto, A. (2006). Bioactive peptides: production and functionality. *International Dairy Journal*, 16(9), 945-960.
- Kumara. J. B. V., & Madhusudhan, B. (2015). Synthesis, characterization and hemocompatibility evaluation of curcumin encapsulated chitosan nanoparticles for oral delivery. *International Journal of Advanced Research*, 3(4), 604-611.
- Kumari, M., Rajak, S., Singh, S. P., Murty, U. S., Mahboob, M., Grover, P., et al. (2013). Biochemical alterations induced by acute oral doses of iron oxide nanoparticles in Wistar rats. *Drug and Chemical Toxicology*, 36(3), 296-305.
- Kurita, K. (1998). Chemistry and application of chitin and chitosan. *Polymer Degradation and Stability*, 59(1-3), 117-120.
- Kurozawa, L. E., Park, K. J., & Hubinger, M. D. (2008). Optimization of the enzymatic hydrolysis of chicken meat using response surface methodology. *Journal of Food Science*, 73(5), C405-C412.

- Lahogue, V., Vallée-Rehel, K., Cuart, M., Haras, D., & Allaupe, P. (2009). Isolation of angiotensin I converting enzyme inhibitory peptides from a fish by-products hydrolysate Tensideal®. *Peptides for Youth*, 483-484.
- Lakshmi, V., & Ghosal, S. (2015). In vitro and in vivo antiamebic potential of actinopyga lecanora (jaeger). *Bangladesh Pharmaceutical Journal*, 18(2), 118-120.
- Laloy, J., Lozano, O., Alpan, L., Mejia, J., Toussaint, O., Masereel, B., et al. (2014). Can TiC nanoparticles produce toxicity in oral administration to rats?. *Toxicology Reports*, 1, 172-187.
- Lanone, S., Rogerieux, F., Geys, J., Dupont, A., Maillot-Marechal, E., Boczkowski, J., et al. (2009). Comparative toxicity of 24 manufactured nanoparticles in human alveolar epithelial and macrophage cell lines. *Particle and Fibre Toxicology*, 6(1), 14.
- Lassoued, I., Mora, L., Nasri, R., Aydi, M., Toldrá, F., Aristoy, M. C., et al. (2015). Characterization, antioxidative and ACE inhibitory properties of hydrolysates obtained from thornback ray (*Raja clavata*) muscle. *Journal of Proteomics*, 128, 458-468.
- Lee, J. K., Hong, S., Jeon, J. K., Kim, S. K., & Byun, H. G. (2009). Purification and characterization of angiotensin I converting enzyme inhibitory peptides from the rotifer, *Brachionus rotundiformis*. *Bioresource Technology*, 100(21), 5255-5259.
- Lee, J. K., Jeon, J. K., & Byun, H. G. (2011). Effect of angiotensin I converting enzyme inhibitory peptide purified from skate skin hydrolysate. *Food Chemistry*, 125(2), 495-499.
- Lee, J. K., Jeon, J. K., Kim, S. K., & Byun, H. G. (2012). 4 Characterization of Bioactive Peptides Obtained from Marine Invertebrates. *Advances in Food and Nutrition Research*, 65, 47.
- Lee, S. H., Qian, Z. J., & Kim, S. K. (2010). A novel angiotensin I converting enzyme inhibitory peptide from tuna frame protein hydrolysate and its antihypertensive effect in spontaneously hypertensive rats. *Food Chemistry*, 118(1), 96-102.
- Li, G. H., Le, G. W., Shi, Y. H., & Shrestha, S. (2004). Angiotensin I-converting enzyme inhibitory peptides derived from food proteins and their physiological and pharmacological effects. *Nutrition Research*, 24(7), 469-486.
- Li, H., & Aluko, R. E. (2010). Identification and inhibitory properties of multifunctional peptides from pea protein hydrolysate. *Journal of Agricultural and Food Chemistry*, 58(21), 11471-11476.



- Li, Y., Sadiq, F. A., Fu, L., Zhu, H., Zhong, M., & Sohail, M. (2016). Identification of angiotensin I-converting enzyme inhibitory peptides derived from enzymatic hydrolysates of Razor Clam (*Sinonovacula constricta*). *Marine Drugs*, *14*(6), 110.
- Li, Y., Zhou, J., Huang, K., Sun, Y., & Zeng, X. (2012). Purification of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide with an antihypertensive effect from loach (*Misgurnus anguillicaudatus*). *Journal of Agricultural and Food Chemistry*, *60*(5), 1320-1325.
- Li, Z., Paulson, A. T., & Gill, T. A. (2015). Encapsulation of bioactive salmon protein hydrolysates with chitosan-coated liposomes. *Journal of Functional Foods*, *19*, 733-743.
- Liang, J., Yan, H., Puligundla, P., Gao, X., Zhou, Y., & Wan, X. (2017). Applications of chitosan nanoparticles to enhance absorption and bioavailability of tea polyphenols: A review. *Food Hydrocolloids*, *69*, 286-292.
- Libby, P., Bonow, R. O., Mann, D. L. & Zipes, D. P. (eds) (2008) *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine* (8th edn), Saunders: Philadelphia, PA.
- Lin, L., Lv, S., & Li, B. (2012). Angiotensin-I-converting enzyme (ACE)-inhibitory and antihypertensive properties of squid skin gelatin hydrolysates. *Food Chemistry*, *131*(1), 225-230.
- Liu, Q., Kong, B., Xiong, Y. L., & Xia, X. (2010). Antioxidant activity and functional properties of porcine plasma protein hydrolysate as influenced by the degree of hydrolysis. *Food Chemistry*, *118*(2), 403-410.
- López-Fandiño, R., Otte, J., & Van Camp, J. (2006). Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. *International Dairy Journal*, *16*(11), 1277-1293.
- Lu, J., Ren, D. F., Xue, Y. L., Sawano, Y., Miyakawa, T., & Tanokura, M. (2010). Isolation of an antihypertensive peptide from alcalase digest of *Spirulina platensis*. *Journal of Agricultural and Food Chemistry*, *58*(12), 7166-7171.
- Lu, Y., Govindasamy-Lucey, S., & Lucey, J. A. (2016). Angiotensin-I-converting enzyme-inhibitory peptides in commercial Wisconsin Cheddar cheeses of different ages. *Journal of Dairy Science*, *99*(1), 41-52.
- Lu, Y., Yang, J., & Segal, E. (2006). Issues related to targeted delivery of proteins and peptides. *The AAPS Journal*, *8*(3), E466-E478.

- Lundstedt, T., Seifert, E., Abramo, L., Thelin, B., Nyström, Å., Pettersen, J., & Bergman, R. (1998). Experimental design and optimization. *Chemometrics and Intelligent Laboratory Systems*, 42(1-2), 3-40.
- Luo, Y. Y., Xiong, X. Y., Tian, Y., Li, Z. L., Gong, Y. C., & Li, Y. P. (2016). A review of biodegradable polymeric systems for oral insulin delivery. *Drug Delivery*, 23(6), 1882-1891.
- Ma, J. J., Mao, X. Y., Wang, Q., Yang, S., Zhang, D., Chen, S. W., et al. (2014). Effect of spray drying and freeze drying on the immunomodulatory activity, bitter taste and hygroscopicity of hydrolysate derived from whey protein concentrate. *LWT-Food Science and Technology*, 56(2), 296-302.
- Ma, J., Guan, R., Chen, X., Wang, Y., Hao, Y., Ye, X., & Liu, M. (2014). Response surface methodology for the optimization of beta-lactoglobulin nano-liposomes. *Food & Function*, 5(4), 748-754.
- Ma, J., Guan, R., Ri, C., Liu, M., Ye, X., & Jiang, J. (2012). Response surface methodology for the optimization of lactoferrin nano-liposomes. *Advance Journal of Food Science and Technology*, 4(5), 249-256.
- Madamba, P. S. (2002). The response surface methodology: an application to optimize dehydration operations of selected agricultural crops. *LWT-Food Science and Technology*, 35(7), 584-592.
- Mahapatro, A., & Singh, D. K. (2011). Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. *Journal of Nanobiotechnology*, 9(1), 55.
- Majeed, M., Hussain, A. I., Chatha, S. A., Khosa, M. K., Kamal, G. M., Kamal, M. A., et al. (2016). Optimization protocol for the extraction of antioxidant components from *Origanum vulgare* leaves using response surface methodology. *Saudi Journal of Biological Sciences*, 23(3), 389-396.
- Mamelona, J., Pelletier, E., Girard-Lalancette, K., Legault, J., Karboune, S., & Kermasha, S. (2007). Quantification of phenolic contents and antioxidant capacity of Atlantic sea cucumber, *Cucumaria frondosa*. *Food Chemistry*, 104(3), 1040-1047.
- Mangalampalli, B., Dumala, N., & Grover, P. (2017). Acute oral toxicity study of magnesium oxide nanoparticles and microparticles in female albino Wistar rats. *Regulatory Toxicology and Pharmacology*, 90, 170-184.
- Manoharan, S., Shuib, A. S., & Abdullah, N. (2017). Structural characteristics and antihypertensive effects of angiotensin-i-converting enzyme inhibitory peptides in the renin-angiotensin and kallikrein kinin systems. *African Journal of Traditional, Complementary, and Alternative Medicines*, 14(2), 383.

- Marealis (2012) Tensiotin®, Available: <http://www.marealis.com/#!Product%20and%20Technology|ca4p> [Retrieved May 27, 2013].
- Maruyama, S., Mitachi, H., Tanaka, H., Tomizuka, N., & Suzuki, H. (1987). Studies on the active site and antihypertensive activity of angiotensin I-converting enzyme inhibitors derived from casein. *Agricultural and Biological Chemistry*, 51(6), 1581-1586.
- Matsufuji, H., Matsui, T., Ohshige, S., Kawasaki, T., Osajima, K., & Osajima, Y. (1995). Antihypertensive effects of angiotensin fragments in SHR. *Bioscience, Biotechnology, and Biochemistry*, 59(8), 1398-1401.
- Matsui, T., Matsufuji, H., Seki, E., Osajima, K., Nakashima, M., & Osajima, Y. (1993). Inhibition of angiotensin I-converting enzyme by *Bacillus licheniformis* alkaline protease hydrolyzates derived from sardine muscle. *Bioscience, Biotechnology, and Biochemistry*, 57(6), 922-925.
- Matsui, T., Tamaya, K., Seki, E., Osajima, K., Matsumoto, K., & Kawasaki, T. (2002a). Absorption of Val-Tyr with in vitro angiotensin I-converting enzyme inhibitory activity into the circulating blood system of mild hypertensive subjects. *Biological and Pharmaceutical Bulletin*, 25(9), 1228-1230.
- Matsui, T., Tamaya, K., Seki, E., Osajima, K., Matsumoto, K., & Kawasaki, T. (2002b). Val- Tyr As a Natural Antihypertensive Dipeptide Can Be Absorbed Into the Human Circulatory Blood System. *Clinical and Experimental Pharmacology and Physiology*, 29(3), 204-208.
- McClements, D. J. (2014). *Nanoparticle-and microparticle-based delivery systems: Encapsulation, protection and release of active compounds*. CRC Press.
- Mehanna, A. S., & Dowling, M. (1999). Liquid chromatographic determination of hippuric acid for the evaluation of ethacrynic acid as angiotensin converting enzyme inhibitor. *Journal of Pharmaceutical and Biomedical Analysis*, 19(6), 967-973.
- Meisel, H. (1997). Biochemical properties of bioactive peptides derived from milk proteins: potential nutraceuticals for food and pharmaceutical applications. *Livestock Production Science*, 50(1-2), 125-138.
- Mendanha, D. V., Ortiz, S. E. M., Favaro-Trindade, C. S., Mauri, A., Monterrey-Quintero, E. S., & Thomazini, M. (2009). Microencapsulation of casein hydrolysate by complex coacervation with SPI/pectin. *Food Research International*, 42(8), 1099-1104.
- Meng, Q. C., & Oparil, S. (1996). Purification and assay methods for angiotensin-converting enzyme. *Journal of Chromatography A*, 743(1), 105-122.

- Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: a powerful approach for structure-based drug discovery. *Current Computer-Aided Drug Design*, 7(2), 146-157.
- Meresa, A., Fekadu, N., Degu, S., Tadele, A., & Geleta, B. (2017). An Ethno Botanical Review on Medicinal Plants Used for the Management of Hypertension. *Journal of Clinical & Experimental Pharmacology*, 7(2), 228.
- Meisel, H., Walsh, D. J., Murray, B. A. & FitzGerald, R. J. (2006) ACE inhibitory peptides. In: *Nutraceutical Proteins and Peptides in Health and Disease* (eds Y. Mine & F. Shahidi), CRC Press, Taylor and Francis Group: New York, NY; pp. 269–315.
- Ming, S. H. E. N. (2001). Investigation on Component and Pharmacology of Sea Cucumber [J]. *Chinese Traditional Patent Medicine*, 10, 021.
- Mohan, A., McClements, D. J., & Udenigwe, C. C. (2016). Encapsulation of bioactive whey peptides in soy lecithin-derived nanoliposomes: influence of peptide molecular weight. *Food Chemistry*, 213, 143-148.
- Mohan, A., Rajendran, S. R., He, Q. S., Bazinet, L., & Udenigwe, C. C. (2015). Encapsulation of food protein hydrolysates and peptides: A review. *RSC Advances*, 5(97), 79270-79278.
- Moinard-Chécot, D., Chevalier, Y., Briançon, S., Beney, L., & Fessi, H. (2008). Mechanism of nanocapsules formation by the emulsion–diffusion process. *Journal of Colloid and Interface Science*, 317(2), 458-468.
- Morais, H. A., da Silva Barbosa, C. M., Delvivo, F. M., Mansur, H. S., de Oliveira, M. C., et al. (2004). Comparative study of microencapsulation of casein hydrolysates in lipospheres and liposomes. *Journal of Food Biochemistry*, 28(1), 21-41.
- Morgan, A., & Archer, J. (1999). Overview: aspects of sea cucumber industry research and development in the South Pacific. *SPC Beche-de-mer Information Bulletin*, 1, 15-17.
- Morris, M. C., Depollier, J., Mery, J., Heitz, F., & Divita, G. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. *Nature Biotechnology*, 19(12), 1173-1176.
- Mosquera, M., Giménez, B., da Silva, I. M., Boelter, J. F., Montero, P., Gómez-Guillén, M. C., et al. (2014). Nanoencapsulation of an active peptidic fraction from sea bream scales collagen. *Food Chemistry*, 156, 144-150.
- Mourão, P. A., & Pereira, M. S. (1999). Searching for alternatives to heparin: sulfated fucans from marine invertebrates. *Trends in Cardiovascular Medicine*, 9(8), 225-232.

- Murray, B. A., & FitzGerald, R. J. (2007). Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. *Current Pharmaceutical Design*, 13(8), 773-791.
- Myers, R. H., Montgomery, D. C. and Anderson-Cook, C. M. (2009) Response Surface Methodology: process and product optimization using designed experiments: John Wiley & Sons, Inc., New York.
- Myers, R. H., Montgomery, D. C., & Anderson-Cook, C. M. (2016). Response surface methodology: process and product optimization using designed experiments: John Wiley & Sons.
- Nagase, H., Enjyoji, K. I., Minamiguchi, K., Kitazato, K. T., Kitazato, K., Saito, H., & Kato, H. (1995). Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III-and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. *Blood*, 85(6), 1527-1534.
- Naghavi, M., Wang, H., Lozano, R., Davis, A., Liang, X., Zhou, M., et al. (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*, 385(9963), 117-171.
- Nasri, M. (2017). Protein Hydrolysates and Biopeptides: Production, Biological Activities, and Applications in Foods and Health Benefits. A Review. *Advances in Food and Nutrition Research*, 81, 109-159.
- Nasti, A., Zaki, N. M., de Leonardis, P., Ungphaiboon, S., Sansongsak, P., Rimoli, M. G., et al. (2009). Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. *Pharmaceutical Research*, 26(8), 1918-1930.
- Ni, H., Li, L., Liu, G., & Hu, S. Q. (2012). Inhibition mechanism and model of an angiotensin I-converting enzyme (ACE)-inhibitory hexapeptide from yeast (*Saccharomyces cerevisiae*). *PloS One*, 7(5), e37077.
- Nielsen, P. M., Petersen, D., & Dambmann, C. (2001). Improved method for determining food protein degree of hydrolysis. *Journal of Food Science*, 66(5), 642-646.
- Nii, Y., Fukuta, K., Yoshimoto, R., Sakai, K., & Ogawa, T. (2008). Determination of antihypertensive peptides from an izumi shrimp hydrolysate. *Bioscience, Biotechnology, and Biochemistry*, 72(3), 861-864.
- Nippon-Supplement (2010). Katsuobushi oligopeptide, Available: [http://www.nippon-sapuri.com/english/product\\_pep.html](http://www.nippon-sapuri.com/english/product_pep.html) [Retrieved May 27, 2013].

- Niu, Z., Conejos-Sánchez, I., Griffin, B. T., O'Driscoll, C. M., & Alonso, M. J. (2016). Lipid-based nanocarriers for oral peptide delivery. *Advanced Drug Delivery Reviews*, 106, 337-354.
- Nongonierma, A. B., & FitzGerald, R. J. (2016). Learnings from quantitative structure–activity relationship (QSAR) studies with respect to food protein-derived bioactive peptides: a review. *RSC Advances*, 6(79), 75400-75413.
- Norris, R., Casey, F., FitzGerald, R. J., Shields, D., & Mooney, C. (2012). Predictive modelling of angiotensin converting enzyme inhibitory dipeptides. *Food Chemistry*, 133(4), 1349-1354.
- Norris, R., Harnedy, P. A., & FitzGerald, R. J. (2013). Antihypertensive peptides from marine sources. *Bioactive Compounds from Marine Foods: Plant and Animal Sources*, 27-56.
- O'Neill, G. J., Egan, T., Jacquier, J. C., O'Sullivan, M., & O'Riordan, E. D. (2015). Kinetics of immobilisation and release of tryptophan, riboflavin and peptides from whey protein microbeads. *Food Chemistry*, 180, 150-155.
- O'Neill, G. J., Egan, T., Jacquier, J. C., O'Sullivan, M., & O'Riordan, E. D. (2014). Whey microbeads as a matrix for the encapsulation and immobilisation of riboflavin and peptides. *Food Chemistry*, 160, 46-52.
- Ohara, H., Matsumoto, H., Ito, K., Iwai, K., & Sato, K. (2007). Comparison of quantity and structures of hydroxyproline-containing peptides in human blood after oral ingestion of gelatin hydrolysates from different sources. *Journal of Agricultural and Food Chemistry*, 55(4), 1532-1535.
- Ono, S., Hosokawa, M., Miyashita, K., & Takahashi, K. (2003). Isolation of Peptides with Angiotensin I- converting Enzyme Inhibitory Effect Derived from Hydrolysate of Upstream Chum Salmon Muscle. *Journal of Food Science*, 68(5), 1611-1614.
- Ortiz, S. E. M., Mauri, A., Monterrey-Quintero, E. S., Trindade, M. A., Santana, A. S., & Favaro-Trindade, C. S. (2009). Production and properties of casein hydrolysate microencapsulated by spray drying with soybean protein isolate. *LWT-Food Science and Technology*, 42(5), 919-923.
- Özer, N. P., Mol, S., & Varlık, C. (2004). Effect of the handling procedures on the chemical composition of sea cucumber. *Turkish Journal of Fisheries and Aquatic Sciences*, 4(2).
- Pacheco, R. G., Vicente, C. P., Zancan, P., & Mourão, P. A. S. (2000). Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. *Blood Coagulation & Fibrinolysis*, 11(6), 563-573.

- Panwar, P., Pandey, B., Lakhera, P. C., & Singh, K. P. (2010). Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. *International Journal of Nanomedicine*, 5, 101.
- Park, E. J., Bae, E., Yi, J., Kim, Y., Choi, K., Lee, S. H., et al. (2010). Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. *Environmental Toxicology and Pharmacology*, 30(2), 162-168.
- Patel, A., Cholkar, K., & Mitra, A. K. (2014). Recent developments in protein and peptide parenteral delivery approaches. *Therapeutic Delivery*, 5(3), 337-365.
- Patel, S. A., Winkel, M., Ali, M. K., Narayan, K. V., & Mehta, N. K. (2015). Cardiovascular Mortality Associated With 5 Leading Risk Factors: National and State Preventable Fractions Estimated From Survey Data Cardiovascular Mortality Associated With Leading Risk Factors. *Annals of Internal Medicine*, 163(4), 245-253.
- Patil, P., & Bhoskar, M. A. N. I. S. H. A. (2014). Optimization and evaluation of spray dried chitosan nanoparticles containing doxorubicin. *International Journal of Current Pharmaceutical Research*, 6(2), 7-15.
- Patil, P., Chavanke, D., & Wagh, M. (2012). A review on ionotropic gelation method: novel approach for controlled gastroretentive gelspheres. *International Journal of Pharmacy and Pharmaceutical Sciences*, 4(4), 27-32.
- Paul, M., & Somkuti, G. A. (2009). Degradation of milk- based bioactive peptides by yogurt fermentation bacteria. *Letters in Applied Microbiology*, 49(3), 345-350.
- Paul, M., & Somkuti, G. A. (2010). Hydrolytic breakdown of lactoferricin by lactic acid bacteria. *Journal of Industrial Microbiology & Biotechnology*, 37(2), 173-178.
- Pérez-Vega, J. A., Olivera-Castillo, L., Gómez-Ruiz, J. Á., & Hernández-Ledesma, B. (2013). Release of multifunctional peptides by gastrointestinal digestion of sea cucumber (*Isostichopus badionotus*). *Journal of Functional Foods*, 5(2), 869-877.
- Peričin, D., Radulović-Popović, L., Vaštag, Ž., Mađarev-Popović, S., & Trivić, S. (2009). Enzymatic hydrolysis of protein isolate from hull-less pumpkin oil cake: application of response surface methodology. *Food Chemistry*, 115(2), 753-757.
- Picariello, G., Iacomino, G., Mamone, G., Ferranti, P., Fierro, O., Gianfrani, C., et al. (2013). Transport across Caco-2 monolayers of peptides arising from *in vitro* digestion of bovine milk proteins. *Food Chemistry*, 139(1), 203-212.

- Pihlanto, A. (2013). Lactic fermentation and bioactive peptides. In *Lactic Acid Bacteria-R & D for Food, Health and Livestock Purposes*. InTech.
- Piktel, E., Niemirowicz, K., Wątek, M., Wollny, T., Deptuła, P., & Bucki, R. (2016). Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. *Journal of Nanobiotechnology*, 14(1), 39.
- Pokharkar, V., Dhar, S., Bhumkar, D., Mali, V., Bodhankar, S., & Prasad, B. L. V. (2009). Acute and subacute toxicity studies of chitosan reduced gold nanoparticles: a novel carrier for therapeutic agents. *Journal of Biomedical Nanotechnology*, 5(3), 233-239.
- Thorkelsson, G., & Kristinsson, H. G. (2009). Bioactive peptides from marine sources. State of art. Report to the NORA fund.
- Pripp, A. H., Isaksson, T., Stepaniak, L., Sørhaug, T., & Ardö, Y. (2005). Quantitative structure activity relationship modelling of peptides and proteins as a tool in food science. *Trends in Food Science & Technology*, 16(11), 484-494.
- Qian, Z. J., Je, J. Y., & Kim, S. K. (2007). Antihypertensive effect of angiotensin I converting enzyme-inhibitory peptide from hydrolysates of bigeye tuna dark muscle, *Thunnus obesus*. *Journal of Agricultural and Food Chemistry*, 55(21), 8398-8403.
- Räder, A. F., Reichart, F., Weinmüller, M., & Kessler, H. (2017). Improving oral bioavailability of cyclic peptides by N-methylation. *Bioorganic & Medicinal Chemistry*.
- Rahman, Z., Zidan, A. S., Habib, M. J., & Khan, M. A. (2010). Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman design. *International Journal of Pharmaceutics*, 389(1), 186-194.
- Raksakulthai, R., & Haard, N. F. (2003). Exopeptidases and their application to reduce bitterness in food: A review. 401-445.
- Rampino, A., Borgogna, M., Blasi, P., Bellich, B., & Cesàro, A. (2013). Chitosan nanoparticles: preparation, size evolution and stability. *International Journal of Pharmaceutics*, 455(1), 219-228.
- Ren, J., Zhao, M., Shi, J., Wang, J., Jiang, Y., Cui, C., et al. (2008). Optimization of antioxidant peptide production from grass carp sarcoplasmic protein using response surface methodology. *LWT-Food Science and Technology*, 41(9), 1624-1632.
- Renukuntla, J., Vadlapudi, A. D., Patel, A., Boddu, S. H., & Mitra, A. K. (2013). Approaches for enhancing oral bioavailability of peptides and proteins. *International Journal of Pharmaceutics*, 447(1), 75-93.



- Rizwan, M., Yahya, R., Hassan, A., Yar, M., Azzahari, A. D., Selvanathan, V., et al. (2017). pH Sensitive hydrogels in drug delivery: Brief history, properties, swelling, and release mechanism, material selection and applications. *Polymers*, 9(4), 137.
- Robinson, P. K. (2015). Enzymes: principles and biotechnological applications. *Essays in Biochemistry*, 59, 1-41.
- Rocha, G. A., Trindade, M. A., Netto, F. M., & Favaro-Trindade, C. S. (2009). Microcapsules of a casein hydrolysate: production, characterization, and application in protein bars. *Revista de Agaroquímica y Tecnología de Alimentos*, 15(4), 407-413.
- Rodríguez-Nogales, J. M., Ortega, N., Perez-Mateos, M., & Busto, M. D. (2007). Experimental design and response surface modelling applied for the optimisation of pectin hydrolysis by enzymes from *Aspergillus niger* CECT 2088. *Food Chemistry*, 101(2), 634-642.
- Roginsky, A., Singh, B., Ding, X. Z., Collin, P., Woodward, C., Talamonti, M. S., et al. (2004). Frondanol®-a5p From the Sea Cucumber, *Cucu-maria Frondosa* Induces Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. *Pancreas*, 29(4), 335.
- Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., et al. (2015). Demographic and epidemiologic drivers of global cardiovascular mortality. *New England Journal of Medicine*, 372(14), 1333-1341.
- Ruiz Ruiz, J. C., Segura Campos, M. R., Betancur Ancona, D. A., & Chel Guerrero, L. A. (2013). Encapsulation of Phaseolus lunatus protein hydrolysate with angiotensin-converting enzyme inhibitory activity. *ISRN Biotechnology*, 2013.
- Ruiz, J. Á. G., Ramos, M., & Recio, I. (2004). Angiotensin converting enzyme-inhibitory activity of peptides isolated from Manchego cheese. Stability under simulated gastrointestinal digestion. *International Dairy Journal*, 14(12), 1075-1080.
- Saito, M., & Hagino, H. (2005). Antihypertensive effect of oligopeptides derived from nori (*Porphyra yezoensis*) and Ala-Lys-Tyr-Ser-Tyr in rats. *Journal of Japanese Society of Nutrition and Food Science (Japan)*.
- Saito, M., Kunisaki, N., Urano, N., & Kimura, S. (2002). Collagen as the major edible component of sea cucumber (*Stichopus japonicus*). *Journal of Food Science*, 67(4), 1319-1322.
- Salimi, A., Maghsoudlou, Y., Jafari, S. M., Mahoonak, A. S., Kashaninejad, M., & Ziaifar, A. M. (2015). Preparation of lycopene emulsions by whey protein concentrate and maltodextrin and optimization by response surface

methodology. *Journal of Dispersion Science and Technology*, 36(2), 274-283.

- Sajeesh, S., Sharma, C. P. (2015). Polymeric Nano/Microparticles for Oral Delivery of Proteins and Peptides. In Handbook of Encapsulation and Controlled Release, 1st ed.; Mishra, M., Ed.; CRC Press: Boca Raton, FL, USA, pp. 1359–1375. ISBN 978-1-4822-3234-9.
- Samaranayaka, A. G., Kitts, D. D., & Li-Chan, E. C. (2010). Antioxidative and angiotensin-I-converting enzyme inhibitory potential of a Pacific hake (*Merluccius productus*) fish protein hydrolysate subjected to simulated gastrointestinal digestion and Caco-2 cell permeation. *Journal of Agricultural and Food Chemistry*, 58(3), 1535-1542.
- Sánchez, A., & Vázquez, A. (2017). Bioactive peptides: A review. *Food Quality and Safety*, 1(1), 29-46.
- San Miguel-Ruiz, J. E., & García-Arrarás, J. E. (2007). Common cellular events occur during wound healing and organ regeneration in the sea cucumber (*Holothuria glaberrima*). *BMC Developmental Biology*, 7(1), 115.
- Sarhan, O. M. M., & Hussein, R. M. (2014). Effects of intraperitoneally injected silver nanoparticles on histological structures and blood parameters in the albino rat. *International Journal of Nanomedicine*, 9, 1505.
- Sato, M., Oba, T., Yamaguchi, T., Nakano, T., Kahara, T., Funayama, K., et al. (2002). Antihypertensive effects of hydrolysates of wakame (*Undaria pinnatifida*) and their angiotensin-I-converting enzyme inhibitory activity. *Annals of Nutrition and Metabolism*, 46(6), 259-267.
- Schneider, T., Westermann, M., & Gleis, M. (2017). In vitro uptake and toxicity studies of metal nanoparticles and metal oxide nanoparticles in human HT29 cells. *Archives of Toxicology*, 1-11.
- Schwabe, C., & Büllsbach, E. E. (2013). *Relaxin and the fine structure of proteins*. Springer Science & Business Media.
- Segura-Campos, M., Chel-Guerrero, L., Betancur-Ancona, D., & Hernandez-Escalante, V. M. (2011). Bioavailability of bioactive peptides. *Food Reviews International*, 27(3), 213-226.
- Sentandreu, M. Á., & Toldrá, F. (2006). A rapid, simple and sensitive fluorescence method for the assay of angiotensin-I converting enzyme. *Food Chemistry*, 97(3), 546-554.
- Seo, H. W., Jung, E. Y., Go, G. W., Kim, G. D., Joo, S. T., & Yang, H. S. (2015). Optimization of hydrolysis conditions for bovine plasma protein using response surface methodology. *Food Chemistry*, 185, 106-111.

- Shaji, J., & Shaikh, M. (2016). Formulation, Optimization, and Characterization of Biocompatible Inhalable D-Cycloserine-Loaded Alginate-Chitosan Nanoparticles for Pulmonary Drug Delivery. *Asian Journal of Pharmaceutical and Clinical Research*, 9, 82–95.
- Sharma, S., Singh, R., & Rana, S. (2011). Bioactive peptides: a review. *International Journal Bioautomation*, 15(4), 223-250.
- Sharma, V., Anderson, D., & Dhawan, A. (2012). Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HepG2). *Apoptosis*, 17(8), 852-870.
- Shegokar, R., & Müller, R. H. (2010). Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. *International Journal of Pharmaceutics*, 399(1), 129-139.
- Sheih, I. C., Fang, T. J., & Wu, T. K. (2009). Isolation and characterisation of a novel angiotensin I-converting enzyme (ACE) inhibitory peptide from the algae protein waste. *Food Chemistry*, 115(1), 279-284.
- Sheriff, S. A., Sundaram, B., Ramamoorthy, B., & Ponnusamy, P. (2014). Synthesis and in vitro antioxidant functions of protein hydrolysate from backbones of Rastrelliger kanagartha by proteolytic enzymes. *Saudi Journal of Biological Sciences*, 21(1), 19-26.
- Shiell, G. (2004). Field observations of juvenile sea cucumbers. *SPC beche-de-mer Information Bulletin*, 20, 6-11.
- Shiozaki, K., Shiozaki, M., Masuda, J., Yamauchi, A., Ohwada, S., Nakano, T., et al. (2010). Identification of oyster-derived hypotensive peptide acting as angiotensin-I-converting enzyme inhibitor. *Fisheries Science*, 76(5), 865-872.
- Shukla, R. K., Kumar, A., Gurbani, D., Pandey, A. K., Singh, S., & Dhawan, A. (2013). TiO<sub>2</sub> nanoparticles induce oxidative DNA damage and apoptosis in human liver cells. *Nanotoxicology*, 7(1), 48-60.
- Sicuro, B., Piccinno, M., Gai, F., Abete, M. C., Danieli, A., Dapra, F., et al. (2012). Food quality and safety of Mediterranean sea cucumbers *Holothuria tubulosa* and *Holothuria polii* in Southern Adriatic Sea. *Asian Journal of Animal and Veterinary Advances*, 7(9), 851-859.
- Soltani, Z., Washco, V., Morse, S., & Reisin, E. (2015). The impacts of obesity on the cardiovascular and renal systems: cascade of events and therapeutic approaches. *Current Hypertension Reports*, 17(2), 7.
- Subtil, S. F., Rocha-Selmi, G. A., Thomazini, M., Trindade, M. A., Netto, F. M., & Favaro-Trindade, C. S. (2014). Effect of spray drying on the sensory and

physical properties of hydrolysed casein using gum arabic as the carrier. *Journal of Food Science and Technology*, 51(9).

- Suetsuna, K. (1998). Separation and identification of angiotensin I-converting enzyme inhibitory peptides from peptic digest of Hizikia fusiformis protein. *Bulletin of the Japanese Society of Scientific Fisheries (Japan)*.
- Suetsuna, K. (2002). Identification of antihypertensive peptides from peptic digest of the short-necked clam *Tapes philippinarum* and the pearl oyster *Pinctada fucata martensii*. *Fisheries Science*, 68(1), 233-235.
- Suetsuna, K., & Chen, J. R. (2001). Identification of antihypertensive peptides from peptic digest of two microalgae, *Chlorella vulgaris* and *Spirulina platensis*. *Marine Biotechnology*, 3(4), 305-309.
- Suetsuna, K., & Nakano, T. (2000). Identification of an antihypertensive peptide from peptic digest of wakame (*Undaria pinnatifida*). *The Journal of Nutritional Biochemistry*, 11(9), 450-454.
- Suetsuna, K., Maekawa, K., & Chen, J. R. (2004). Antihypertensive effects of *Undaria pinnatifida* (wakame) peptide on blood pressure in spontaneously hypertensive rats. *The Journal of Nutritional Biochemistry*, 15(5), 267-272.
- Sugawara, T., Zaima, N., Yamamoto, A., Sakai, S., Noguchi, R., & Hirata, T. (2006). Isolation of sphingoid bases of sea cucumber cerebroside and their cytotoxicity against human colon cancer cells. *Bioscience, Biotechnology, and Biochemistry*, 70(12), 2906-2912.
- Suh, H. J., Cho, S. J., Whang, J. H., Lee, H., & Yang, H. C. (1997). Characterization of angiotensin converting enzyme inhibitor from squid hydrolysate. *Food Science and Biotechnology*, 6(2), 122-124.
- Sun, H., Liu, D., Li, Y., Tang, X., & Cong, Y. (2014). Preparation and in vitro/in vivo characterization of enteric-coated nanoparticles loaded with the antihypertensive peptide VLPVPR. *International Journal of Nanomedicine*, 9, 1709.
- Sun, L., Wu, S., Zhou, L., Wang, F., Lan, X., Sun, J., et al. (2017). Separation and Characterization of Angiotensin I Converting Enzyme (ACE) Inhibitory Peptides from *Saurida elongata* Proteins Hydrolysate by IMAC-Ni<sup>2+</sup>. *Marine Drugs*, 15(2), 29.
- Tanaka, M., Watanabe, S., Wang, Z., Matsumoto, K., & Matsui, T. (2009). His-Arg-Trp potently attenuates contracted tension of thoracic aorta of Sprague-Dawley rats through the suppression of extracellular Ca<sup>2+</sup> influx. *Peptides*, 30(8), 1502-1507.

- Tang, H. Q., Xu, M., Rong, Q., Jin, R. W., Liu, Q. J., & Li, Y. L. (2016). The effect of ZnO nanoparticles on liver function in rats. *International Journal of Nanomedicine*, 11, 4275.
- Tavares, G. M., Croguennec, T., Carvalho, A. F., & Bouhallab, S. (2014). Milk proteins as encapsulation devices and delivery vehicles: applications and trends. *Trends in Food Science & Technology*, 37(1), 5-20.
- Tavares, T. G., Contreras, M. M., Amorim, M., Martín-Álvarez, P. J., Pintado, M. E., Recio, I., et al. (2011). Optimisation, by response surface methodology, of degree of hydrolysis and antioxidant and ACE-inhibitory activities of whey protein hydrolysates obtained with cardoon extract. *International Dairy Journal*, 21(12), 926-933.
- Taylor, T. M., Gaysinsky, S., Davidson, P. M., Bruce, B. D., & Weiss, J. (2007). Characterization of antimicrobial-bearing liposomes by  $\zeta$ -potential, vesicle size, and encapsulation efficiency. *Food Biophysics*, 2(1), 1-9.
- Theodore, A. E., & Kristinsson, H. G. (2007). Angiotensin converting enzyme inhibition of fish protein hydrolysates prepared from alkaline- aided channel catfish protein isolate. *Journal of the Science of Food and Agriculture*, 87(12), 2353-2357.
- Thompson, A. K., Mozafari, M. R., & Singh, H. (2007). The properties of liposomes produced from milk fat globule membrane material using different techniques. *Le Lait*, 87(4-5), 349-360.
- Thorin, E., Shreeve, S. M., Thorin-Trescases, N., & Bevan, J. A. (1997). Reversal of endothelin-1 release by stimulation of endothelial  $\alpha_2$ -adrenoceptor contributes to cerebral vasorelaxation. *Hypertension*, 30(4), 830-836.
- Tian, F., Zhang, X., Tong, Y., Yi, Y., Zhang, S., Li, L., et al. (2005). PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities *in vitro* and *in vivo*. *Cancer Biology & Therapy*, 4(8), 874-882.
- Tong, Y., Zhang, X., Tian, F., Yi, Y., Xu, Q., Li, L., et al. (2005). Philinopside a, a novel marine- derived compound possessing dual anti- angiogenic and anti- tumor effects. *International Journal of Cancer*, 114(6), 843-853.
- Tonon, R. V., Grosso, C. R., & Hubinger, M. D. (2011). Influence of emulsion composition and inlet air temperature on the microencapsulation of flaxseed oil by spray drying. *Food Research International*, 44(1), 282-289.
- Trouiller, B., Reliene, R., Westbrook, A., Solaimani, P., & Schiestl, R. H. (2009). Titanium dioxide nanoparticles induce DNA damage and genetic instability *in vivo* in mice. *Cancer Research*, 69(22), 8784-8789.

- Tsai, J. S., Chen, J. L., & Pan, B. S. (2008). ACE-inhibitory peptides identified from the muscle protein hydrolysate of hard clam (*Meretrix lusoria*). *Process Biochemistry*, 43(7), 743-747.
- Tsugita, M., Morimoto, N., & Nakayama, M. (2017). SiO<sub>2</sub> and TiO<sub>2</sub> nanoparticles synergistically trigger macrophage inflammatory responses. *Particle and Fibre Toxicology*, 14(1), 11.
- Turner, A. J., & Hooper, N. M. (2002). The angiotensin-converting enzyme gene family: genomics and pharmacology. *Trends in Pharmacological Sciences*, 23(4), 177-183.
- Udenigwe, C. C. (2014). Bioinformatics approaches, prospects and challenges of food bioactive peptide research. *Trends in Food Science & Technology*, 36(2), 137-143.
- Udenigwe, C. C., & Aluko, R. E. (2012). Food protein- derived bioactive peptides: production, processing, and potential health benefits. *Journal of Food Science*, 77(1).
- Udenigwe, C. C., Lin, Y. S., Hou, W. C., & Aluko, R. E. (2009). Kinetics of the inhibition of renin and angiotensin I-converting enzyme by flaxseed protein hydrolysate fractions. *Journal of Functional Foods*, 1(2), 199-207.
- Van der Ven, C., Gruppen, H., de Bont, D. B., & Voragen, A. G. (2002). Optimisation of the angiotensin converting enzyme inhibition by whey protein hydrolysates using response surface methodology. *International Dairy Journal*, 12(10), 813-820.
- Vargas Casanova, Y., Rodríguez Guerra, J. A., Umaña Pérez, Y. A., Leal Castro, A. L., Almanzar Reina, G., García Castañeda, J. E., et al. (2017). Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB-468 and MDA-MB-231 Breast Cancer Cell Lines. *Molecules*, 22(10), 1641.
- Vasantharaja, D., Ramalingam, V., & Aadinaath Reddy, G. (2015). Oral toxic exposure of titanium dioxide nanoparticles on serum biochemical changes in adult male Wistar rats. *Nanomedicine Journal*, 2(1), 46-53.
- Vercruyse, L., Morel, N., Van Camp, J., Szust, J., & Smagghe, G. (2008). Antihypertensive mechanism of the dipeptide Val-Tyr in rat aorta. *Peptides*, 29(2), 261-267.
- Vermeirssen, V., Van Camp, J., & Verstraete, W. (2002). Optimisation and validation of an angiotensin-converting enzyme inhibition assay for the screening of bioactive peptides. *Journal of Biochemical and Biophysical Methods*, 51(1), 75-87.

- Vermeirssen, V., Van Camp, J., & Verstraete, W. (2004). Bioavailability of angiotensin I converting enzyme inhibitory peptides. *British Journal of Nutrition*, 92(3), 357-366.
- Vieira, R. P., Mulloy, B., & Mourão, P. A. (1991). Structure of a fucose-branched chondroitin sulfate from sea cucumber. Evidence for the presence of 3-O-sulfo-beta-D-glucuronosyl residues. *Journal of Biological Chemistry*, 266(21), 13530-13536.
- Vishkaei, S. M., Ebrahimpour, A., Abdul-Hamid, A., Ismail, A., & Saari, N. (2016). Angiotensin-I Converting Enzyme (ACE) Inhibitory and Anti-Hypertensive Effect of Protein Hydrolysate from *Actinopyga lecanora* (Sea Cucumber) in Rats. *Marine Drugs*, 14(10), 176.
- Volpe, M., Danser, A. J., Menard, J., Waeber, B., Mueller, D. N., Maggioni, A. P., et al. (2012). Inhibition of the renin–angiotensin–aldosterone system: is there room for dual blockade in the cardiorenal continuum?. *Journal of Hypertension*, 30(4), 647-654.
- Wada, Y., & Lönnerdal, B. (2014). Bioactive peptides derived from human milk proteins—mechanisms of action. *The Journal of Nutritional Biochemistry*, 25(5), 503-514.
- Wang, J., Hu, J., Cui, J., Bai, X., Du, Y., Miyaguchi, Y., et al. (2008). Purification and identification of a ACE inhibitory peptide from oyster proteins hydrolysate and the antihypertensive effect of hydrolysate in spontaneously hypertensive rats. *Food Chemistry*, 111(2), 302-308.
- Wang, M., Zhao, T., Liu, Y., Wang, Q., Xing, S., Li, L., et al. (2017). Ursolic acid liposomes with chitosan modification: Promising antitumor drug delivery and efficacy. *Materials Science and Engineering: C*, 71, 1231-1240.
- Wang, X., Wu, S., Xu, D., Xie, D., & Guo, H. (2011). Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies. *Journal of Chemical Information and Modeling*, 51(5), 1074-1082.
- Wang, X., Yu, H., Xing, R., & Li, P. (2017). Characterization, Preparation, and Purification of Marine Bioactive Peptides. *BioMed Research International*, 2017.
- Watermeyer, J. M., Kröger, W. L., O'Neill, H. G., Sewell, B. T., & Sturrock, E. D. (2008). Probing the basis of domain-dependent inhibition using novel ketone inhibitors of angiotensin-converting enzyme. *Biochemistry*, 47(22), 5942-5950.

- Wen, J., Hu, C., & Fan, S. (2010). Chemical composition and nutritional quality of sea cucumbers. *Journal of the Science of Food and Agriculture*, 90(14), 2469-2474.
- Were, L. M., Bruce, B., Davidson, P. M., & Weiss, J. (2004). Encapsulation of nisin and lysozyme in liposomes enhances efficacy against *Listeria monocytogenes*. *Journal of Food Protection*, 67(5), 922-927.
- Wijesekara, I., & Kim, S. K. (2010). Angiotensin-I-converting enzyme (ACE) inhibitors from marine resources: prospects in the pharmaceutical industry. *Marine Drugs*, 8(4), 1080-1093.
- Wijesekara, I., Qian, Z. J., Ryu, B., Ngo, D. H., & Kim, S. K. (2011). Purification and identification of antihypertensive peptides from seaweed pipefish (*Syngnathus schlegeli*) muscle protein hydrolysate. *Food Research International*, 44(3), 703-707.
- Witt, K. A., & Davis, T. P. (2006). CNS drug delivery: opioid peptides and the blood-brain barrier. *The AAPS Journal*, 8(1), E76-E88.
- Wong, K., & Cheung, P. C. (2001). Influence of drying treatment on three *Sargassum* species 2. Protein extractability, in vitro protein digestibility and amino acid profile of protein concentrates. *Journal of Applied Phycology*, 13(1), 51-58.
- World Health Organization. (2013). A global brief on hypertension: World Health Day 2013. *Geneva: WHO*.
- Wu, H., He, H. L., Chen, X. L., Sun, C. Y., Zhang, Y. Z., & Zhou, B. C. (2008). Purification and identification of novel angiotensin-I-converting enzyme inhibitory peptides from shark meat hydrolysate. *Process Biochemistry*, 43(4), 457-461.
- Wu, J., Aluko, R. E., & Nakai, S. (2006). Structural Requirements of Angiotensin I-Converting Enzyme Inhibitory Peptides: Quantitative Structure-Activity Relationship Modeling of Peptides Containing 4-10 Amino Acid Residues. *Molecular Informatics*, 25(10), 873-880.
- Wu, S., Sun, J., Tong, Z., Lan, X., Zhao, Z., & Liao, D. (2012). Optimization of hydrolysis conditions for the production of angiotensin-I converting enzyme-inhibitory peptides and isolation of a novel peptide from lizard fish (*Saurida elongata*) muscle protein hydrolysate. *Marine Drugs*, 10(5), 1066-1080.
- Xu, Y., & Du, Y. (2003). Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. *International Journal of Pharmaceutics*, 250(1), 215-226.



- Yang, C. L., Chen, J. P., Wei, K. C., Chen, J. Y., Huang, C. W., & Liao, Z. X. (2017). Release of Doxorubicin by a Folate-Grafted, Chitosan-Coated Magnetic Nanoparticle. *Nanomaterials*, 7(4), 85.
- Yea, C. S., Ebrahimpour, A., Hamid, A. A., Bakar, J., Muhammad, K., & Saari, N. (2014). Winged bean [*Psophorcarpus tetragonolobus* (L.) DC] seeds as an underutilised plant source of bifunctional proteolysate and biopeptides. *Food & Function*, 5(5), 1007-1016.
- Yea, C. S., Tan, W. K., & Saari, N. (2015). Preparation and characterisation of nanoliposomes containing winged bean seeds bioactive peptides. *Journal of Microencapsulation*, 32(5), 488-495.
- Yokota, D., Moraes, M., & Pinho, S. C. (2012). Characterization of lyophilized liposomes produced with non-purified soy lecithin: a case study of casein hydrolysate microencapsulation. *Brazilian Journal of Chemical Engineering*, 29(2), 325-335.
- Yolmeh, M., & Jafari, S. M. (2017). Applications of response surface methodology in the food industry processes. *Food and Bioprocess Technology*, 10(3), 413-433.
- Yoshikawa, M., Fujita, H., Matoba, N., Takenaka, Y., Yamamoto, T., Yamauchi, R., et al. (2000). Bioactive peptides derived from food proteins preventing lifestyle-related diseases. *Biofactors*, 12(1- 4), 143-146.
- You, L., Zhao, M., Cui, C., Zhao, H., & Yang, B. (2009). Effect of degree of hydrolysis on the antioxidant activity of loach (*Misgurnus anguillicaudatus*) protein hydrolysates. *Innovative Food Science & Emerging Technologies*, 10(2), 235-240.
- Young, D., & Mine, Y. (2009). Functional bioactive proteins and peptides in nutrigenomics. *Nutrigenomics and Proteomics in Health and Disease: Food Factors and Gene Interactions*, 129-144.
- Yours, M., & Howell, N. (2015). Antioxidant and ACE inhibitory bioactive peptides purified from egg yolk proteins. *International Journal of Molecular Sciences*, 16(12), 29161-29178.
- Yu, T., Zhao, S., Li, Z., Wang, Y., Xu, B., Fang, D., et al. (2016). Enhanced and Extended Anti-Hypertensive Effect of VP5 Nanoparticles. *International Journal of Molecular Sciences*, 17(12), 1977.
- Zarei, M., Forghani, B., Ebrahimpour, A., Abdul-Hamid, A., Anwar, F., & Saari, N. (2015). In vitro and in vivo antihypertensive activity of palm kernel cake protein hydrolysates: Sequencing and characterization of potent bioactive peptides. *Industrial Crops and Products*, 76, 112-120.

- Zhang, B., & Zhang, X. (2013). Separation and nanoencapsulation of antitumor polypeptide from *Spirulina platensis*. *Biotechnology Progress*, 29(5), 1230-1238.
- Zhang, H., Wu, F., Li, Y., Yang, X., Huang, J., Lv, T., et al. (2016). Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone. *Beilstein Journal of Nanotechnology*, 7, 1861.
- Zhang, J. A. A., & Pawelchak, J. (2000). Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC/cholesterol liposomes under accelerated conditions: Part 1: Lipid hydrolysis. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(3), 357-364.
- Zhang, T., Nie, S., Liu, B., Yu, Y., Zhang, Y., & Liu, J. (2015). Activity prediction and molecular mechanism of bovine blood derived angiotensin I-converting enzyme inhibitory peptides. *PloS One*, 10(3), e0119598.
- Zhao, L., Yang, G., Shi, Y., Su, C., & Chang, J. (2015). Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance. *Journal of Nanobiotechnology*, 13(1), 57.
- Zhao, Y., Li, B., Dong, S., Liu, Z., Zhao, X., Wang, J., et al. (2009). A novel ACE inhibitory peptide isolated from *Acaudina molpadioidea* hydrolysate. *Peptides*, 30(6), 1028-1033.
- Zhao, Y., Li, B., Liu, Z., Dong, S., Zhao, X., & Zeng, M. (2007). Antihypertensive effect and purification of an ACE inhibitory peptide from sea cucumber gelatin hydrolysate. *Process Biochemistry*, 42(12), 1586-1591.
- Zheng, Y., Su, C., Zhao, L., & Shi, Y. (2017). Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy. *Journal of Nanobiotechnology*, 15(1), 28.
- Zhong, Y., Khan, M. A., & Shahidi, F. (2007). Compositional characteristics and antioxidant properties of fresh and processed sea cucumber (*Cucumaria frondosa*). *Journal of Agricultural and Food Chemistry*, 55(4), 1188-1192.
- Zhu, C. Z., Zhang, W. G., Zhou, G. H., Xu, X. L., Kang, Z. L., & Yin, Y. (2013). Isolation and identification of antioxidant peptides from Jinhua ham. *Journal of Agricultural and Food Chemistry*, 61(6), 1265-1271.
- Zhuang, Y., Sun, L., Zhang, Y., & Liu, G. (2012). Antihypertensive effect of long-term oral administration of jellyfish (*Rhopilema esculentum*) collagen peptides on renovascular hypertension. *Marine Drugs*, 10(2), 417-426.